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ABSTRACT 
 
Structural Studies of Terpenoid Biosynthesis and Bacterial Cell Division.  
(August 2006) 
Dong Yang, B.S., Zhe Jiang University 
Chair of Advisory Committee:  Dr. James C. Sacchettini 
 
 
 
            The objective of this work is to investigate the structures of two nucleotide 
binding proteins: mevalonate kinase (MVK) and FtsZ.  
           MVK is the key enzyme involved in terpenoid biosynthesis. In this study, we 
solved the crystal structures of the M. jannaschii MVK apoprotein, as well as the protein 
in complex with ligands. Its fold was analyzed and firmly established within the GHMP 
kinase family, in which homoserine kinase (HSK), phosphomevalonate kinase and 
galactokinase also belong. Structural analysis in combination with enzyme kinetics 
studies revealed the mechanism of this enzyme upon substrate binding, catalysis and 
inhibition. In particular, the phosphate-binding loop was found to be critically involved 
in the binding of nucleotides and terpenoids, via the interaction with a di-phosphate 
moiety from the ligand. An enzymatic reaction mechanism was constructed based on our 
structural data and it is consistent with kinetics studies from the literature. In this 
mechanism, the invariant residue Asp 155 functions as a general base that increases the 
nucleophilicity of the phosphoryl acceptor. Finally, a virtual screening study has been 
 iv
performed to explore the ligand binding potential of MVK. Compounds predicted to 
bind MVK were tested and analyzed.  
           FtsZ is a prokaryotic homologue of tubulin that forms the apparatus for bacterial 
cell division. The structure of a crystal filament of the M. tuberculosis FtsZ complexed 
with GDP was described in this study. It shows an anti-parallel, left-handed double 
helical architecture. Compared with the straight crystal filament revealed earlier by other 
groups, the catalytic T7 loop in our structure is found to be outside the nucleotide 
binding site, indicating the GTPase is inactive. Furthermore, the buried surface area in 
our crystal filament is less, probably suggesting the helical FtsZ filament is less stable. 
We therefore proposed that the hydrolysis of GTP and the releasing of the γ-phosphate 
group will trigger the rearrangement of the FtsZ fibler, characterized by the exclusion of 
the T7 loop, which might lead to a less stable helical filament and would be the first step 
for the disassembly of FtsZ polymer.  
 
 
            
 
 
 
 
 
 v
DEDICATION 
           To my parents and sister, for their love and support. To my friends for their help 
and encouragement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi
ACKNOWLEDGEMENTS 
           First of all, I am thankful to Dr. James Sacchettini, my advisor, for giving me 
opportunities to do research in his lab and also giving me valuable advice and guidance 
during these years. I am also thankful to other members of my advisory committee: Dr. 
Patricia Liwang, Dr. James Hu and Dr. Terry Thomas, for their suggestions and 
discussion on my work.  
           Second, I have to thank colleagues in Dr. Sacchettini’s lab, particularly Dr. Lance 
Shipman, as he led me into the world of crystallography when I just finished my rotation 
and joined this lab. I thank other members or former members in our group, particularly 
Dr. Remo Perozzo, Dr. Christoph Eicken, Dr. Sheng Ye, Dr. Clare Smith, Dr. Chih-chin 
Huang, Dr. Yoonsang Cho, Dr. Sudharsan Sridharan, Ms. Stephanie Swanson, Ms. Arati 
Ramesh and Mr. Feng Wang, for their advice and help at various stages during my work.  
           My research also involves several collaborators. Particularly, I have to thank Dr. 
David Borhani (Abbott Bioresearch Center) and Ms. E. Lucile White (Southern 
Research Institute), for their initial work on FtsZ and their generosity in supplying me 
full-length FtsZ proteins. I have to thank Mr. Christos Savva for his kind help in 
performing EM studies on FtsZ filaments. I am also thankful to Drs. A. Ian Scott and 
Charles Roessner for providing us initial clones of MVK.  
           Finally, my work could not be completed without help from the supporting staff 
in this department, particularly the administrative assistants for Dr. Sacchettni: Ms. 
Karen Hodges and the late Dr. Linda Fisher. 
 
 vii
NOMENCLATURE 
ADP                                 Adenosine 5’-diphosphate    
ADPβS                             Adenosine 5’-(βthiol)-diphosphate 
AMP                                 Adenosine 5’-monophosphate 
AMPPCP                         Adenosine 5’-(β, γ-methylene)-diphosphate 
APS                                 Advanced Photon Source 
ATP                                 Adenosine 5’-triphosphate 
CAMD                            Center for Advanced Microstructures and Devices 
CDP                                Cytidine 5’-diphosphate 
CDP-ME                         4-diphosphocytidyl-2-C-methyl-erythritol     
CDP-ME2P                     4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate 
CMP                               Cytidine 5’-monophosphate 
CoA                                 Coenzyme A 
CTP                                 Cytidine 5’-triphosphate 
DEAE                              Diethylaminoethyl 
DMAPP                           Dimethylallylpyrophosphate 
DMSO                             Dimethyl Sulfoxide 
DTT                                 Dithiothreitol 
dUTP                               2'-deoxyuridine 5'-triphosphate 
DXP                                 1-Deoxy-D-xylulose 5-phosphate 
EM                                    Electron Microscopy 
FPP                                  Farnesyl Pyrophosphate 
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GAP                                 GTPase Activating Protein 
GDP                                 Guanosine 5’-diphosphate 
GDPβS                             Guanosine 5’-(βthiol)-diphosphate 
GGPP                               Geranylgeranyl Diphosphate 
GMPPCP                          Guanosine 5'-(β, γ-methylene)-diphosphonate 
GMPPNP                          Guanosine 5’-(β, γ-imido)-triphosphate 
GPP                                   Geranyl Pyrophosphate 
GTP                                  Guanosine 5’-triphosphate 
GTPγS                              Guanosine 5'-(3-O-thio)triphosphate 
HEPES                              N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic Acid 
HIDS                                 Hyperimmunoglobulinemia D Syndrome 
HMB-PP                          (E)-4-hydroxy-3-methyl-but-2-enylpyrophosphate 
HMG                                3-Hydroxy-3-methyl glutaryl   
HSK                                  Homoserine Kinase 
IPP                                    Isopentenyl Pyrophosphate 
IPTG                                Isopropyl-beta-D-thiogalactopyranoside 
ITP                                   Inosine 5’-triphosphate 
LB                                    Luria Bertani Broth 
LDH                                 Lactate Dehydrogenase 
LDL                                  Low Density Lipoprotein 
MAD                               Multiwavelength Anomalous Dispersion 
MECDP                           2-C-methyl-D-erythritol 2,4-cyclodiphosphate 
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MEP                                Methylerythritol Phosphate 
MIR                                 Multiple Isomorphous Replacement 
MPD                                2-methyl-2,4-pentanediol 
MVK                               Mevalonate Kinase 
NAD+                               Nicotinamide Adenine Dinucleotide  (oxidized form) 
NADH                             Nicotinamide Adenine Dinucleotide  (reduced form) 
NADPH                           Nicotinamide Adenine Dinucleotide Phosphate (reduced form) 
NCS                                 Non-crystallography symmetry 
NDP                                Any Diphosphonucleotide 
PAGE                              Polyacrylamide Gel Electrophoresis  
PCR                                 Polymerase Chain Reaction 
PIP                                  Di-iodobis-ethylenediamine-diplatinum II nitrate   
PK                                   Pyruvate Kinase 
PMSF                              Phenylmethylsulfonyl Fluoride 
RGS                                 Regulators of G Protein Signaling 
SAD                                Singlewavelength Anomalous Dispersion 
SIR                                  Single Isomorphous Replacement   
SDS                                Sodium dodecyl sulphate  
Se-Met                            Selenium Methionine 
SRE                                 Sterol Regulatory Element 
Tris                                  Tris(hydroxymethyl) Aminomethene 
UPPS                               Undecaprenyl Pyrophosphate Synthetase                   
 x
UTP                                 Uridine 5’-triphosphate 
X                                      Any Amino Acid Residue 
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CHAPTER I 
 INTRODUCTION TO STRUCTURAL BIOLOGY 
Scope of Structural Biology 
           If a cell could be viewed as a factory, the architecture of the assembly line and the 
design of each machine would be essential for understanding how this factory works. 
Since its birth in mid 20th century, structural biology, in combination with biochemical 
and genetic methods, has provided critical pieces of information for decoding biological 
secrets. For example, without the fiber diffraction data, Watson and Crick would not 
have been able to deduce the double helical model of DNA that, even after several 
generations, still inspires our imagination.  
           The earliest subjects studied by structural biology were enzymes or other ligand 
binding proteins. By co-crystallizing the ligand with the protein, one can understand the 
mechanism of substrate recognition and catalysis. Comparison of ligand bound and 
apoprotein structures also reveals protein conformational changes upon ligand binding 
and supports the concept of “induced fit”. One success story was the work done by 
Perutz three decades ago (1). By studying the crystal structures of the oxy and deoxy 
forms of hemoglobin, he discovered that the binding of oxygen led to the rearrangement 
of the protein quaternary structure by the movement of the iron relative to the porphyrin 
ring, which resulted in the breakage of a salt bridge. This structural observation  
________________ 
This dissertation follows the style and format of Journal of Biological Chemistry. 
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explained the basis for cooperativity of oxygen binding in hemoglobin.             
           Transition state analogs can sometimes be co-crystallized with the enzyme 
forming a tight “activated complex”, which provides more direct information regarding 
the catalysis. More advances in the aspects of “kinetic protein crystallography” have 
been made recently. For example, by using the “trigger-freeze” method (2), one might 
trap a reaction intermediate in the crystal. This approach, however, is limited by the 
relatively slow rate of cooling (about 0.1s), which sometimes fails to capture the 
intermediate. An alternative approach is time resolved crystallography that takes 
advantage of Laue diffraction (2). Events in the time frame of less than 1 ns could be 
captured by this method. The limitation of this approach, however, is the quality of the 
data collected. Therefore, time resolved crystallography and trapping methods can be 
used in complementation to better understand the kinetic questions at hand. Finally, 
advances in synchrotron radiation have pushed the diffraction limit of some crystals to 
beyond 1 Å, which permits the visualization of hydrogen atoms as well as multiple 
conformations of side chains (3). As a result, a plausible catalytic mechanism can be 
distinguished from its alternatives.  
           Many macromolecules are in fact drug targets. Recent breakthroughs in the field 
of structural biology have aided in the increased output of the number of crystal 
structures solved. As a result, much interest in the field has occurred in the 
pharmaceutical sector, which has led to successful target and inhibitor development. For 
example, protein kinases and their various roles in carcinogenesis are important targets 
for developing anti-tumor drugs. Studies on BCR-Abl kinase in complex with anti-
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cancer drug Gleevec not only sheds light on how this compound is effective, but also 
provides clues for developing inhibitors against other protein kinase targets (4). Another 
example is the HIV protease. Structural studies on the binding mode of its inhibitors play 
significant roles in improving their efficacy (5). Another important drug is INH, a first 
line anti-tuberculosis drug. Crystallographic research reveals that it forms an adduct with 
the cofactor NADH and occupies the active site of the drug target, enzyme InhA, which 
blocks the synthesis of fatty acids in mycobacterium (6).   
           Although we can learn a great deal by studying individual macromolecules, a 
complete understanding of the cell factory is not possible without an intact picture of the 
assembly line. Not surprisingly, structural biology has progressed into the domain of 
large macromolecular complexes (7). Structures of the ribosome, signal recognition 
particle, ATP synthase, RNA polymerase, DNA polymerase, nucleosome, proteasome, 
chaperones, endosomal sorting complexes and also multi-enzyme complexes such as 
rubisco and pyruvate dehydrogenase have been reported. Many of these were solved by 
X-ray crystallography. Other methods, particularly single particle cryo-EM and electron 
tomography, are making an important contribution to this field (8). Fitting atomic crystal 
structures into low resolution EM density has been a standard approach to study the very 
large complexes that are refractory to crystallographic method alone. Success stories 
include the structural revelation of the bacteriophage T4 infection mechanism, the 
interaction by the ribosome with the signal recognition particle and also the ribosome 
protein-conducting channel complex, etc.  
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           Another frontier of structural biology lies with integral membrane proteins which 
include channels, transporters, receptors and protein complexes involved in electron 
transfer. As much cellular processes take place at or on the membrane, the structural 
solution of these proteins is indispensable for addressing important biological questions. 
They also represent more than 70% of current drugs targets. The structural determination 
of membrane proteins is a tough problem for crystallographers. The first membrane 
crystal structures were of the photosynthetic reaction centers. Membrane proteins 
involved in respiration, such as succinate:quinone oxidoreductase, cytochrome bc1 
complex and cytochrome c oxidase (designated as complexes II, III and IV), followed 
suit. Crystal structures of ion channels emerged at the turn of this century. Structures of 
transporters were reported only years later, first ABC transporters and then lactose 
permease. Now membrane protein crystallography has been progressed into the era of 
membrane protein structural genomics, which advocates the rapid expression, 
purification and crystallization of a large number of membrane proteins from a variety of 
species.   
           Technology has always set the pace for structural biology. The development of 
better instrumentation for X-ray diffraction, NMR and EM has and still remains the 
driving force for this field. The vast improvement in computing power is another 
important factor. The progress in molecular biology, protein expression systems and 
robotic technologies has also made important contributions. As this dissertation will be 
focused on X-ray crystallography, we will now start to discuss the basic theories for 
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protein crystallization and crystal diffraction, which will then be followed by practical 
issues regarding protein phasing and structural refinement.  
Introduction to Crystallography 
Theory of protein crystallization 
           A protein crystal is a type of protein aggregate formed by orderly deposition of 
protein molecules. During crystallization, the protein is kept in a supersaturated state in 
which a two-stage process takes place: in the first stage (nucleation stage), a few protein 
molecules start to associate to form the nuclei that have the same intermolecular contacts 
as that of the final crystal; in the second stage (crystal growth stage), more protein 
molecules deposit onto the nuclei and visible crystals appear (9). This process is 
dependent upon many factors such as precipitants, salts (particularly divalent cation), pH, 
polyamines, chaotropes, linkers and detergent (10).  Therefore, for a particular protein to 
be crystallized, a variety of crystallization conditions, generally organized as a sparse 
matrix for crystal screening, are tested before a condition is found.  
           In addition, kinetic parameters, including the mixing ratio between protein and 
precipitant, the method for establishing equilibrium, as well as the temperature are also 
significant during crystallization (11). One technique that is worth special consideration 
is the seeding method (12). Generally, the energy barrier for nucleation is higher than 
that for crystal growth. Therefore, the stage for nucleation requires a higher 
supersaturation level. In order to limit the number of nuclei and produce larger crystals, 
it is sometimes advantageous to separate these two stages, which can be accomplished 
by seeding preformed crystals or microcrystals into a new drop with a lower saturation 
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level. The conditions in the new drop are not sufficient for nucleation per se but are 
supportive for growth from the seeded nuclei.  
Theory of crystal diffraction 
           X-rays are electromagnetic radiation with a very short wavelength occurring at a 
range from 0.1 to 1000 Å and can be described mathematically as follows. 
                                                         Aexp[iα],                                                             (1. 1) 
where A is the amplitude of the wave while α is the phase angle. A wave can be 
represented as a vector in a two-dimentional axial system, with the length of the vector 
as the amplitude and the angle with the real axis as the phase angle. Adding waves is 
thereby the summation of vectors and can be calculated accordingly (Figure 1a). 
Depending on the difference in phase angles, the amplitude of the summated wave can 
be any values between 0 and the simple summation of the amplitudes of the original 
waves. For example, if two waves have the same amplitude A and are in phase (with the 
same phase angle), the amplitude of their summation will be 2A, which is defined as 
constructive interference. If two waves are 180◦ out of phase, the amplitude of their 
summation will be zero, which is destructive interference.  
           When an incoming X-ray wave encounters an electron, it will be scattered as a 
photon is first absorbed by the electron and then re-emitted at the same wavelength. In a 
system with multiple electrons, each electron will scatter X-rays, and of the scattered X-
ray waves should be summated according to the vector algebra described above. In a 
crystal, because of its periodicity, only certain scattered reflections are allowed to exist. 
This situation can be explained as follows (Figure 1b). Suppose we could cut a crystal 
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into a series of parallel reflection planes with space d, and there exists a parallel incident 
X-ray light. The X-ray beam has wavelength λ and an angle with the plane θ. Since there 
are almost infinite numbers of such planes in a crystal, it is easy to imagine the only 
condition for any scattered light is that all scattered light is exactly in phase, or because 
of the destructive interference they will eventually be cancelled out with each other. To 
fulfill this requirement, the path difference of incident and scattered light from each 
plane should be an integral of the incident wavelength λ, which is called the Bragg’s law 
and is expressed in the following form. 
                                                     2sinθ = n λ /d              (n is an integral.).                 (1. 2) 
           Bragg’s law can be used to predict where the scattered light (called reflection) 
will appear in space. For a three dimensional crystal, the sets of reflection planes can be 
described by three integers h, k, l. The reflection generated by each set of planes is 
described by its structural factor F(h, k, l). 
           For a crystal whose unit cell contains large numbers of electrons, the structural 
factor of each reflection is the Fourier transform of the electron density in the cell.                  
                           F(h, k, l) = V ∫ ∫ ∫ ρ(x, y, z) exp [2πi(hx+ky+lz)]dxdydz,                   (1. 3) 
where ρ is the electron density and V is the unit cell volume; x, y, z is the coordinates 
within the unit cell. 
           And because of the properties of the Fourier transform, one can also calculate the 
electron density, if the structural factor F(h, k, l)  is known.  
              ρ(x, y, z) = (1/V)  Σ Σ Σ |F(h,k,l)| exp [-2πi(hx+ky+lz)+iα(h, k, l)]          (1. 4) 
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Figure 1 Basics of Diffraction.  
 
a. The Basics of Vector Summation 
Vector F1 and F2 are summated to generate vector F3. The phase angle of F1 is “a” 
and the phase angle of F3 is “b”.  
 
b. Bragg’s Law 
The extra distance of the second beam (AB+BC) should be an integer multiple of 
the wavelength, in order for the scattered beams to be constructively interfered.     
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(|F(h, k, l)| is the amplitude of the structural factor and can be directly converted from 
the measurable intensity of each reflection. α(h, k, l) is the phase angle of the structural 
factor. As α(h, k, l) can not be determined directly, it has to be inferred from either 
experimental phasing methods or a structural model.)          
           When the phase information is from the structural model, a 2Fo-Fc map is 
calculated, in which the amplitude is 2|F(h,k,l)obs|-|F(h,k,l)cal|, which can decrease the 
possible bias of the map towards the model. (|F(h,k,l)obs| and |F(h,k,l)cal| are the 
amplitudes measured from the observation and that calculated from the model, 
respectively; α(h, k, l)cal is the phase angle calculated from the model.) The equation is 
given in the following form: 
   ρ(x, y, z) = (1/V) Σ Σ Σ (2|F(h,k,l)obs|-|F(h,k,l)cal|) exp [-2πi(hx+ky+lz)+iα(h, k, l)cal].                     
                                                                                                                                      (1. 5) 
Data collection and processing  
           In most crystallography labs, the X-ray radiation is generated using a copper 
based rotating anode that produces a specific wavelength near 1.54 Å. This approach is 
limited by low intensity and the inability to adjust wavelength. This problem is 
commonly overcome by synchrotron radiation that is generated from circulating 
electrons traveling near the speed of light. Synchrotron can produce X-rays at least two 
orders of magnitude stronger than that of conventional sources. Synchrotron radiation is 
also tunable that is it can produce radiation over a wide range of wavelengths, and a 
suitable wavelength can be selected using a monochromator. 
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           The X-ray detector is the equipment used to record each reflection during the 
diffraction experiment. Image plates and CCD are the most commonly used devices. The 
data collection process is normally performed at low temperature using liquid nitrogen, 
and the crystal is protected by a cryoprotectant that prevents the formation of ice on the 
crystal. Data collection at low temperatures limits the diffusion of hydroxyl free radicals, 
which minimizes the radiation damages done to the crystal. 
           Crystals are characterized by their internal symmetry. Data processing is used to 
determine the symmetry of the crystal and assign the indices (h, k, l) of each reflection. 
This process is divided into two steps. First indexing is performed in which each frame 
is processed and the crystal is assigned to belong to one of the 14 Bravais lattice. The 
indices of the reflections are determined at this step and parameters, such as detector to 
crystal distance, crystal orientation, beam position, are also refined. The second step is 
scaling, in which reflections throughout the dataset are brought to the same scale and 
symmetrically equivalent reflections are averaged. Space groups can also be determined 
at this stage. The program HKL2000 (13) can accomplish both indexing and scaling. 
Other programs are also available, including MOSFLM (indexing) (14) and SCALA 
(scaling) (15).  
Obtaining experimental phases 
           As discussed earlier, two strategies are available to determine phase angles. We 
will discuss the experimental phasing method here, and the molecular replacement 
method will be described in the next section.  
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           The attachment of heavy atom(s) can remarkably affect the intensity of the 
reflections, and can be explored to infer the protein phase angles. There are two general 
approaches to obtain experimental phases from heavy atoms: by simply comparing the 
intensity difference between derivative and native crystals or by exploring the 
anomalous scattering. 
           MIR is the phasing method that adopts the first approach. Its strategy is to first 
calculate the amplitude contributed by heavy atoms (|FH|) by subtracting the amplitude 
of the native crystal from that of the derivatized crystal. A special type of Fourier 
transform, called the Patterson function, is then used to calculate a Patterson map for the 
heavy atoms, using only the heavy atom amplitude |FH|.  
                    P (u, v, w) = (1/V) Σ |FH|2 cos [2π(hu+kv+lw)]                                        (1. 6) 
The Patterson map is a vector map and the peaks on this map represent the vector 
pointing from one atom to another in the unit cell. The actual atom positions can be 
solved from the Patterson map provided their number is small, which is the case for 
heavy atoms. The locations of heavy atoms lead to their phase angles (αH), and with the 
native and derivative amplitudes, can be used to solve the protein phase angles (αP).   
           Anomalous scattering is enhanced when the incident X-ray wavelength 
approaches the absorption edge of the element. Consequently, the scattered light will 
have an imaginary component, whose phase angle is 90◦ retarded from the normal 
component.  
                                                          f = 0f + f´ + i f´´                                                   (1. 7) 
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(f is the overall atomic scattering factor. 0f is for the “normal” scattering. For anomalous 
scattering, f´ is the component that has same phase angle with the “normal” scattering, 
and f´´ is the component that has phase angle 90◦ retarded from the “normal” scattering. i 
means f´´ is the imaginary component.) With the presence of anomalous scattering, the 
amplitude of the Bijvoet pair (|F(h, k, l)| and |F(-h, -k, -l)|) will be different. This 
difference, called anomalous difference, can provide information for phasing purposes.  
 
 
Figure 2 Principle of MAD. 
 
FT is the vector for normal scattering from all atoms; FA is the vector for 
anomalous scattering; λF is the vector for total scattering under a particular 
wavelength; and ∆φ is the phase angle difference. During the MAD experiment, the 
amplitude of the total scattering (|λF|) is observed.  
 
 
           The most commonly used method for this purpose is MAD (Figure 2), in which 
datasets are collected at multiple wavelengths. Two wavelengths near the absorption 
edge are of particular importance. They are λ1 (peak), where f’’ has the highest value, 
and λ2 (inflection), where it is at the absorption edge and f’ has the most negative value. 
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Normally, one or two more wavelengths at least 100eV from the absorption edge are 
also needed as high or low energy remote sets. Data from a MAD experiment are 
sufficient to locate anomalous scatterers and calculate protein phase angles. Because 
only one crystal is needed for structural determination, MAD circumvents the problem 
of non-isomorphism and is very powerful for solving protein structures.   
           Many programs are available for solving structures. One such program is SOLVE 
(16). It provides an automatic approach to solve Patterson functions and is used for both 
MIR and MAD experiments. For MAD structural solution, it first analyzes the Patterson 
map calculated using |FA| (Figure 2) to find a few heavy atom positions. These partial 
heavy atom structures are used as the “seed” for further calculations, during which a 
difference Fourier map is made and top peaks are picked as additional heavy atom sites 
and added into the partial structure. The new partial structure is then refined and scored. 
The whole process is itinerated until a complete heavy atom structure and protein phases 
are produced. Each solution is evaluated by Z-scores that estimate its agreement with 
Patterson functions, the cross-validation from the difference Fourier, the figure of merit 
and the boundary between solvent and macromolecule. In general, for two heavy atoms, 
a good solution should have an overall Z-score at least 5-10. Recently, direct methods, 
previously only used in small molecule structure determination, have been implemented 
(17) in programs such as SHELXD (18) and RANTAN (19) to locate heavy atoms. They 
have advantages over Patterson based methods when there are many heavy atoms (e.g. 
more than 20) in an asymmetric unit.  
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Figure 3 Principle of Molecular Replacement. 
 
a. The Procedure of Molecular Replacement 
The model (left) is first rotated (R) to generate proper orientation. It is then 
translated within the unit cell (T) to be located to the proper position (right).  
 
b. The Property of the Patterson Map 
A three atom molecule is shown in left (real space) and the intramolecular vectors 
derived from the molecule are shown in the right (Patterson space). As the molecule 
rotates 90°, the corresponding intramolecular vectors also rotate 90°.  
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           Normally, the initial heavy atom sites are refined, so the protein phase angles 
calculated based on these sites will be more accurate. Traditionally, this step is 
performed based on a least-squares approach. More recent programs, in particular 
SHARP (20), implement a maximal likelihood based method, which avoids the problem 
of biases and the improper assumption regarding the native dataset. The latter is 
particularly important for MAD datasets, as there is no real “native” dataset from such 
experiments.   
Phasing by molecular replacement 
           Available protein structures, if sufficiently similar, can be used as a model to 
provide phase information that, in combination with the experimental amplitudes, may 
be used to calculate the electron density map for the unknown protein. Normally, the 
space group and unit cell of the model structure are different from that of the unknown 
protein. The approach to correctly locate the model structure is called molecular 
replacement.   
           The position of a model is defined by its three rotational and three translational 
parameters. In order to reduce the computational cost, most molecular replacement 
methods, such as AMORE (21), CNS (22) and MOLREP (23), divide the process into 
separate rotational and translational search steps (Figure 3a). The first step is based on a 
property of the Patterson function in which the intramolecular Patterson vectors only 
depend on the orientation of the model and will rotate as the model rotates (Figure 3b). 
Therefore, by rotating the model, one can compare the Patterson function calculated 
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from the model with that from the data, and a significant overlap should indicate the 
correct orientation of the model.  
           During the translational search step, the correctly orientated model will move 
throughout the unit cell to find the maximal correlation coefficient that indicates the 
correct solution. The success of molecular replacement is mostly dependent on the 
quality of the model, both its similarity with the unknown structure and its completeness 
(the fraction of the asymmetric unit the model covers).  
           The above approach is limited by possible errors during the rotational search step. 
For a less perfect model, this traditional approach may fail to generate a clear solution. 
Although a simultaneous search of all six parameters may overcome these limitations, 
this type of search is computationally costly. One program that has partly solved this 
problem is the evolutionary based program EPMR (24). During an EPMR run, a 
population of trial solutions with six random parameters is first generated. The 
correlation coefficient of each solution is calculated and compared.  Those with the 
highest correlation coefficient are the “fittest” solutions and are retained as “survivors”. 
These solutions will produce the next generation by introducing normally distributed 
“mutations” in their six parameters, and the process continues for many generations 
thereafter. For some poorer models, a true solution could only be found after running 
more than thirty generations.           
Phase improvement (Density modification) 
           In many cases, the initial phases can be improved to generate a better electron 
density map that aids in simplifying the model building. One of the most commonly used 
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methods is solvent flattening, which is based on the knowledge that in an electron 
density map, there is greater density area in the region where the protein molecule 
occupies and less density area in the bulk solvent region. If the solvent-protein boundary 
can be identified, the electron density and the protein phase angles can be improved 
significantly simply by applying a low constant to the solvent region (25). This approach 
has been implemented into many programs such as DM (26), RESOLVE (27) and CNS. 
A related program SOLOMAN (28) also improves the electron density, but instead of 
applying a constant to the solvent region (flattening), it inverts the density in the solvent 
region by a flipping factor (flipping). 
           Another important phase improvement approach is based on the fact that there is 
often more than one molecule in an asymmetric unit, and some of these molecules might 
be identical (e.g. homodimers). Therefore, NCS operators can be identified and by 
averaging the electron density of the equivalent copies, density and phase angles can be 
improved (29). This approach is called molecular averaging and has also been 
implemented in programs DM, RESOLVE and CNS. The combination of solvent 
flattening (or flipping) with molecular averaging is very efficient at removing the phase 
ambiguity associated with experimental phasing. These methods are necessary for 
producing an interpretable electron density map when data from only one heavy atom 
derivative (SIR) or one wavelength of anomalous diffraction (SAD) are available. 
           If phases are from a structural model, the resulting electron density map may be 
in danger of being biased by the model, which might lead to erroneous conclusions. 
There are methods, such as omit maps (calculate a 2Fo-Fc map using a partial model 
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structure with the questionable part deleted), perturbation of the model (“shaking”) and 
map averaging, that substantially decrease the model bias.  Shake ‘n’ wARP (30) is one 
program that implements several of these approaches in combination, including omitting 
part of structure, “shaking” the model, maximum likelihood refinement, real space 
placing and removing dummy-atoms from the density then averaging six maps derived 
from differently perturbed models. As a result, the final electron density map from shake 
‘n’ wARP run have less phase bias and overall have a better clarity and contrast.  
Model building and refinement  
           Model building is performed in a graphic program, such as SPOCK (31), O (32) 
and XtalView (33). For a map generated from experimental derived phases, manual 
fitting of structural elements into the electron density is performed, as no structural 
model is available. Normally, one will first generate secondary structure elements (α-
helix, β-strand) composed of poly-alanine, using programs such as MOLEMAN (34) and 
fitting these elements into the density. The alanine residues can then be “mutated” into 
actual amino acids, once the protein sequence in that region is recognized. Sometimes 
before model building, a skeleton (bones) representation of the electron density is 
generated by programs such as MAPMAN (35), which can simplify the view of the map.  
Model building can also be partially done automatically using ArpWarp (36), 
RESOLVE or TEXTAL (37), though manual residue adjustments and regional 
rebuilding are still necessary to complete the model. If the map is generated from 
molecular replacement derived phases, one will have a mostly correct model to start with. 
Therefore, the model building process is focused on the rebuilding of the initial model. 
 19
Regions that do not fit the density are deleted and rebuilt, and side chains are “mutated” 
according to the actual sequence.  
           The protocol for model refinement is dependant on the abundance and quality of 
the data. If the resolution is very low (e. g. 4.0 Å or lower), the data to parameter ratio is 
low and rigid body refinement programs, such as CORELS (38), are more useful. In the 
normal resolution range, atomic coordinates and isotropic temperature factors are refined 
in the programs CNS or REFMAC (39). In these methods, stereochemical restrains are 
incorporated and the relative weight between the stereochemical and X-ray restrains can 
be adjusted according to the data and model quality. Generally, a higher weight is 
assigned to the X-ray restrain when the resolution is high and the opposite is true when 
the resolution is low. If the resolution is even higher (better than 1.5 Å), anisotropic 
temperature factor refinement or even unrestrained refinement may be performed, 
because of the high data to parameter ratio. Simulated annealing, available in programs 
CNS and PHENIX (40), can sometimes be performed to free the model from the local 
minimum. 
           The progress of model refinement is monitored by the R factor, which evaluates 
the difference between amplitudes observed from data and those calculated from the 
model. The equation is given as the following:  
                             R=  (Σ ||F(h, k, l)obs|-|F(h, k, l)cal||) /( Σ |F(h, k,l)obs|).                       (1. 8)  
In order to check the validity of each refinement step and avoid over-refinement, about 
5-10% data are randomly selected as the free set before the first round of refinement (41). 
The rest data are assigned as the work set to be used for refinement. The R factor 
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calculated using the data from the work set is designated as Rwork, while the R factor 
calculated based on the data from the free set is Rfree. After each refinement step, both 
Rwork and Rfree should decrease. The divergence of these two R factors indicates over-
refinement of the model and should invalidate the particular refinement step that leads to 
this divergence. 
Theory of Structural Based Drug Design 
Virtual screening 
            High throughput screening based on combinatorial libraries has already become 
the backbone for the pharmaceutical industry. The complimentary approach is virtual 
screening, in which the structure of the target protein is used for screening in silico over 
a large compound database. This approach has the benefit of lower costs, more 
compounds to screen and higher speeds. Successes include the designing of inhibitors 
against the carbonic anhydrase II, farnesyl transferase, DNA gyrase, estrogen receptor 
and thrombin (42). At its current technological level, virtual screening is not expected to 
correctly rank all possible ligands. Instead, the goal is to identify compounds worthwhile 
for further characterization or optimization. The overall process of virtual screening can 
be divided into four steps: i) preparation of a compound library and protein target; ii) 
molecular docking; iii) post processing; iv) in vitro testing for inhibition.  
           In the first step, the compound library is prepared, usually by various filters that 
limit the number of compounds for docking. One general filter is the “rule of five”. It 
states that a drug-like molecule should have molecular weight less than 500, logP value 
less than 5, less than 5 hydrogen donors and less than 10 hydrogen acceptors. This rule is 
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a good predictor of the bioavailability of the compound. Other filters are more specific 
and are based on the analysis of the substructures associated with known inhibitors, and 
the chemical stability or toxicity. Because many libraries only supply a two dimensional 
structure, the compounds have to be converted into three dimensions using programs 
such as CONCORD (42). Care also needs to be taken when properly assigning the 
tautomers and ionization state of the chemical.  
           In some cases, the homology model of a protein can be used as the target; 
however, the most commonly used target is an experimentally derived structure, 
normally from X-ray diffraction or NMR. There is a quality requirement for these 
structures. For example, X-ray crystal structures should have an R factor lower than 0.25, 
resolution higher than 2.5 Å and good overall geometry (43). In addition, the active site 
chosen for docking should not have high temperature factors. Water molecules in the 
crystal structure are generally deleted, unless they play important roles in the protein 
structure or ligand binding (42). 
           The ideal approach for docking is to treat both protein and ligand as flexible 
entities. However, because of the limitation of computing power, most programs only 
explore the flexibility of the ligand. One common approach is the incremental 
construction algorithm implemented in the program FLEXX (44). During docking by 
FLEXX, the ligand is first divided into small fragments. A base fragment is first selected 
and docked into the active site as a rigid body. The remaining fragments are added to the 
base fragment to incrementally build the ligand. This approach is capable of exploring 
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the flexibility of the ligand in reasonable computing hours and has shown to reproduce 
about 70% of experimentally determined protein-ligand complex structures (44).  
           The docking results are monitored by scoring functions that predict how well the 
ligand binds in a particular docked pose. Scoring functions can be based on a force field, 
such as AMBER or CHARMM, which provide the advantage of accuracy but are 
generally slow for calculation (42). Other scoring functions are empirically based. They 
use an additive approximation and are faster (42). The scoring function provided by 
FLEXX is one example. However, because they are derived from binding affinity data 
from a small set (about 100) of protein-ligand complexes, bias towards these datasets is 
inevitable (42). To address this issue, knowledge based functions such as PMF or 
Drugscore have recently been developed. They are derived from the structures of 
protein-ligand complexes. Because it does not rely on binding affinity data, these 
functions are derived from a much larger data pool and are less biased (42).  
           These scoring functions are not perfect. To minimize the number of false 
positives, consensus scoring is generally performed in the post processing step (42). For 
example, during the FLEXX docking, in addition to the build-in FLEXX scoring 
function, a series of other scoring functions, including ChemScore, G_Score, D_Score 
and PMF_Score, can also be produced. A consensus score is given on a scale of 1 to 5 
after evaluating all of these scores. A high consensus score suggests the agreement 
among different scoring functions, indicating the correctness of the scoring and the 
reliability of the docking result.  A low consensus score generally indicates the 
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inadequacy of the scoring procedure that has been used and, as a result, the 
corresponding docking result should at best be treated with extreme caution.  
De novo drug design and fragment based screening 
           Both high throughput screening and virtual screening are based on a large library 
of drug-like molecules. One common problem is that many of these compounds have 
relatively large molecular weights (ranged from 250 to 600 Da) and contain functional 
groups that do not directly contribute to the binding of the target molecule. As 
summarized from the “rule of five”, larger molecules are generally associated with poor 
bioavailability. The current lead optimization process routinely increases the molecular 
weight on average about 80 Da (45, 46). Therefore, the hits from either high throughput 
screening or virtual screening may not necessarily lead to drug candidates.  
           Methods have been developed to directly design drug molecules, based on the 
binding properties of individual fragments. Computer based de novo design basically 
places fragments into the binding pocket of the target protein (45). Subsequent 
optimization links different fragments to build the potential ligand. Programs 
implemented with this approach include LUDI, LEAPFROG, SPROUT, etc. This field is 
still under development. The difficulties include the inaccuracy of docking and the poor 
“synthesizability” of the resulting compounds. 
           A more experimentally oriented approach is fragment based screening (46, 47). 
Instead of “drug-like molecules”, fragments whose molecular weights are within the 
range of 100 to 350 Da are tested. This approach is heavily dependent on structural 
biology techniques, such as NMR and X-ray crystallography, because fragments only 
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exhibit low binding affinities (mM to 30 µM) and are difficult to detect using bioassays 
(46). The structures of the target protein in complex with the fragments provide the 
actual binding mode of the fragment, and drug leads can then be identified by either 
evolution from the fragment or assembling several fragments together. Compared with 
high throughput screening, the fragment based method is focused on the ligand 
efficiency, meaning a high value for the average free energy for binding per atom (46). 
In contrast to hundreds of thousands compounds tested in high throughput screening, 
only hundreds or at most a few thousands fragments need to be tested in the fragment 
based approach. As structural information is directly available for the fragment based 
method, fewer synthesis attempts might be needed for optimization, which can also be 
cost effective.  
 Overview of Chapters 
           Our general interest is to investigate the structure and function of biologically 
important proteins using X-ray crystallography. Proteins that bind nucleotides play 
important roles in biological systems. They either function as enzymes using the bound 
nucleotide as the substrate, such as kinases, or as regulatory or structural proteins in 
which hydrolysis of the bound nucleotide acts as a “switch” for protein conformation 
and, lastly functionality, such as G proteins, tubulin, actin, etc. This dissertation is 
focused on two nucleotide binding proteins: MVK and FtsZ, with the former as an 
example of a kinase and the latter as a case of a structural protein.   
           Chapter I already presented an overview of structural biology, particularly the 
discussion on X-ray crystallography and structural based drug design. It has provided an 
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explanation of the techniques used and prepares the reader for the description of results 
generated using these methods in the following chapters. 
           Chapter II and III are focused on MVK. Chapter II gives the background 
information about terpenoid synthesis and the properties of MVK. Chapter III discusses 
the structures of both apo and ligand bound forms of MVK. It also provides a detailed 
description of the processes of MAD phasing on MVK crystals. The goal of this chapter 
is to establish the fold of MVK within the GHMP kinase family and also to establish its 
mechanism of substrate binding, catalysis and inhibition. To achieve this, kinetic studies 
are also incorporated. The final part of this chapter is virtual screening and hit validation 
using MVK as a target protein. Some initial hits have been identified and attempts to 
optimize them are summarized. The limitation of the current virtual screening procedure 
is also discussed.   
           Chapter IV and V are focused on FtsZ. Chapter IV introduces the background of 
bacterial cell division and the role that FtsZ plays. Chapter V describes the investigation 
into the polymerization of FtsZ. It starts from the characterization, both by EM and 
biochemical methods, of the M. tuberculosis FtsZ polymerization. The main part of this 
chapter is the description of a crystal structure of FtsZ at 4.0 Å that reveals a double 
helical crystal filament. The significance of this macromolecular assembly is discussed. 
Finally, a working model for FtsZ mechanism based on the conformational changes 
upon GTP hydrolysis is suggested. The process of molecular replacement phasing and 
structural refinement at a low resolution is also discussed in detail.  
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           Chapter VI is the final chapter. It provides a brief summary on the research 
described by this dissertation as well as the future directions that can still be pursued.  
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CHAPTER II  
BACKGROUND OF TERPENOID BIOSYNTHESIS AND MVK 
Terpenoid Biosynthesis 
Terpenoids 
           Terpenoids are the most diversified chemicals.  More than 20,000 terpenoids have 
been characterized and hundreds more are reported every year (48). Important 
biologically active compounds, such as sterols, retinol and dolichol belong to the 
terpenoid family. Other biologically important molecules, such as ubiquinone, 
chlorophyll and Ras protein (49) are modified by terpenoids, which is necessary for their 
membrane association and proper function. Many drugs, including Taxol (50) and 
Artemisinin (51), are derived from terpenoids. Natural rubber, as a widely used material, 
is also a terpenoid. (Table 1) 
           Terpenoids are produced from the polymerization of a five carbon unit – IPP. The 
successive head to tail polymerization of IPP forms GPP, FPP and GGPP. The further 
cyclization creates a family of highly diversified molecules. Many of these are natural 
products that are produced from plants and insects and probably have their original roles 
as defensive substances or pheromones. Two FPP molecules can also undergo head to 
head condensation to form a C30 compound that is then converted into squalene. The 
cyclization of squalene is the first step that precedes a series of reactions leading to the 
formation of cholesterol.   
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  Table 1 Representative Terpnenoids. 
 
Structure  Name Comments  
 
 
 GPP  Precursor of Monoterpenes 
 
  
Limonene Oil from Citrus Rind 
 
  
Camphor Oil from Camphor wood  
 
  
Menthol 
Main Component of 
Peppermint Oil 
 
  
Linalool 
Main Component of Indian 
Basil Oil 
 
  
FPP 
Precursor of Sesquiterpenes 
and steroids 
 
 
O
P
OO
O
P
OO
O
O
OH
OH
O
P
OO
O
P
OO
O
 29
Table 1 Continued.  
Structure  Name  Comments 
 
  Zingiberene 
Essential Oil from 
Ginger 
 
  
5-epi-
Aristolochene 
Precursor of 
antifungal phytoalexin 
capsidiol 
 
 
Artemisinin Anti-Malaria Drug 
 
 
Germacrene A 
Precursor of Many 
Sesquiterpenes 
 
 
 Squalene Precuror of Steroids 
    
 
 
O
O
O
O
O
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Table 1 Continued.  
Structure  Name  Comments 
 
  
Cholesterol 
Eukaryotic 
Membrane 
Stabilization 
 
  
GGPP 
Precursor of 
Diterpenes 
 
  
Salvinorin C 
Extracted from 
Hallucinogenic 
Mexican Mint 
 
  
Taxol  Anti-Tumor Drug 
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Table 1 Continued.  
Structure  Name  Comments 
 
 
 
all-trans-β-
Carotene Precursor of Vitamin A 
 
 
Dolichol 
Phosphate 
Transport 
Oligosaccharide  
 
 
Natural 
Rubber Material 
    
 
 
 
 
O P O
O
O
n
 
n=15-19
*
*
n
 
n=11000 to 20000
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           The biosynthesis of IPP is present in all three domains of life. The mevalonate 
dependent pathway is present mostly in eukaryote and archaea (52). It uses acetyl-CoA 
its starting block. The non-mevalonate pathway was discovered in the 1990S as the 
alternative pathway used by most bacteria and plant plastids (53). The non-mevalonate 
pathway uses pyruvate and glyceraldehydes 3-phosphate as the carbon source. Some 
gram positive bacteria, however, use the mevalonate pathway instead (52).   
The mevalonate pathway 
           The first step of this pathway is the formation of acetoacetyl-CoA by the 
condensation of two molecules of acetyl-CoA, catalyzed by acetoacetyl-CoA thiolase.  
HMG-CoA is then produced from acetyl-CoA and acetoacetyl-CoA by HMG-CoA 
synthase. The next step is to reduce HMG-CoA to mevalonate by HMG-CoA reductase. 
Mevalonate is converted to 5-phosphomevalonate by MVK, then to 5-
pyrophosphomevalonate by phosphomevalonate kinase. The last step is a 
decarboxylation reaction catalyzed by pyrophosphomevalonate decarboxylase, which 
forms IPP from 5-pyrophosphomevalonate (Figure 4). IPP can then be converted to 
DMAPP by IPP isomerase.   
           Among enzymes involved in the mevalonate pathway, HMG-CoA reductase is 
the best characterized (54). Type I HMG-CoA reducatases are distributed in eukaryotes 
and archae and have an N-terminal transmembrane anchoring domain (54). Type II 
enzymes are distributed mostly in bacteria. They lack the transmembrane domain but 
have a unique C-terminal flap domain instead (54). Type I HMG-CoA reductases are the 
target for statins, a class of popular drugs used for cholesterol control. All statin drugs  
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Figure 4 The Mevalonate Dependent Pathway for IPP Biosynthesis. 
 34
are composed of a HMG-like moiety and a hydrophobic ringed moiety. Structures of 
statin and human HMG-CoA reductase complexes show that the HMG-like moiety binds 
to the HMG binding pocket (55). The hydrophobic moiety of statins binds to a shallow 
hydrophobic groove that is part of the CoA binding site. This hydrophobic groove is 
flexible, as it undergoes reorganization according to the hydrophobic moiety of the drug, 
which may explain the properties of different drugs.  As the enzyme for the limiting step, 
HMG-CoA reductase is regulated by a variety of factors. For example, insulin can 
stimulate its dephosphorylation, which promotes its activity. Glucagen has the opposite 
effect (56). The activity of HMG-CoA reductase is also regulated by its synthesis and 
degradation. As a feedback control mechanism, cholesterol is able to reduce the 
expression of HMG-CoA reductase as well as to promote its degradation (56). 
           MVK will be reviewed later. Phosphomevalonate kinases can be classified into 
two distinct families. The majority of this enzyme, distributed in plants, fungi and some 
bacteria, belongs to the well characterized GHMP family, as with MVK. The second 
group of the phosphomevalonate kinase, distributed in animals, belongs to the P-loop 
kinases family. Pyrophosphomevalonate decarboxylase catalyzes the conversion of 
phosphomevalonate to IPP. The reaction involves the transferring of the phosphate 
group from ATP to the 3’-hydroxyl group of 5’-pyrophosphomevalonate, which is 
followed by the decarboxylation and the leaving of the phosphate group. It is still 
unclear about the exact mechanism of this reaction (57). 
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The non-mevalonate pathway 
           The first step in the non-mevalonate pathway is the condensation of one pyruvate 
with one glyceraldehydes 3-phosphate to form DXP, catalyzed by the thiamine 
dependent enzyme DXP synthase. DXP is then converted to MEP by DXP 
reductoisomerase. A CMP moiety is transferred to MEP to form CDP-ME by CDP-ME 
synthase. CDP-ME is then phosphorylated by CDP-ME kinase, producing CDP-ME2P. 
Cyclization of CDP-ME2P by MECDP synthase forms MECDP. The ring opening 
reaction on CDP-ME2P is then catalyzed by HMB-PP synthase. The product, HMB-PP, 
is reduced by HMB-PP reductase, which produces IPP and DMAPP (Figure 5). 
           The first enzyme in this pathway, DXP synthase, shares homology with 
transketolases as well as the E1 component of pyruvate dehydrogenase. These proteins 
are thiamine dependent enzymes that transfer a 2-carbon unit. Recent studies suggest 
that ketoclomazone, a breakdown product of herbicide clomazone, is an inhibitor of 
DXP synthase (58). The second enzyme DXP reductoisomerase catalyzes a 
rearrangement reaction in which the C-4 carbon migrates to the C-2 atom. One potential 
drug targeting DXP reductoisomerase is the herbicide fosmidomycin that inhibits this 
enzyme by mimicking its substrate (59). Recently, fosmidomycin was found to show 
good activities against Plasmodium spp., the pathogenic agent of malaria (60).   
           CDP-ME synthase, CDP-ME kinase and MECDP synthase have all been 
characterized structurally (61, 62, 63). The structure of MECDP synthase shows a 
homotrimer, with the substrate binding site at the interface between two monomers. 
Interestingly, in its central cavity there is an additional density that resembles a GPP  
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Figure 5 The Non-Mevalonate Pathway for IPP Biosynthesis. 
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molecule. It is possible that GPP plays some regulatory roles in the enzyme activity, as 
also occurs in MVK. HMB-PP synthase (GcpE in E. coli) converts MECDP to HMB-PP. 
Two cysteine residues are indicated as catalytic residues (64). The formation of a 
disulfide bond between these two residues is presumed to be essential for catalysis. 
HMB-PP reductase (LytB in E. coli) is a NADPH dependent enzyme and catalyzes the 
reduction of HMB-PP (64). This step generates both IPP and DMAPP, in about 5:1 ratio 
(64). A carbocation intermediate was proposed to be involved in the reaction and 
responsible for forming both products (64).  
Chain elongation 
           Beginning with DMAPP, successive additions of IPP unit creates a family of 
polyprenyl diphosphate, including GPP, FPP and GGPP. The chain elongation is 
catalyzed by prenyltransferases (also known as polyprenyl diphosphate synthase). The 
majority of those are E-polyprenyl diphosphate synthase that create trans products (65). 
The E-type enzymes all contain a conserved aspartate-rich motif DDXXD that binds the 
substrate via bridging Mg2+ ions (66). Other prenyltransferases belong to the Z-type that 
catalyzes the formation of the cis double bond. These enzymes do not have sequence 
homology with E-prenyltransferases. DDXXD motifs have not been identified in Z-type 
enzymes. Instead, they may use an aspartate and a glutamate to bind polyprenyl 
pyrophosphate and IPP, via a bridging Mg2+ ion, as demonstrated by the crystal structure 
of UPPS (67).   
           The mechanism for chain elongation is an electrophilic alkylation (68) (Figure 6a). 
First, the leaving of the pyrophosphate group from DMAPP or polyprenyl  
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Figure 6 Prenyltransferase. 
 
a. The Mechanism of the Prenyl-transfer Reaction 
  
b. Chain Length Control Mechanism of Prenyltransferase 
The terpenoid chain binds to a long tunnel and its length is limited by the distance 
between the DDXXD motif and a bulky residue (represented by a phenyalanine 
side chain in this figure). 
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pyrophosphate creates a carbocation that makes an attack on the C3-C4 double bond of 
IPP. The carbocationic intermediate is then eliminated, creating a double bond at C2 
position. The chain-length of the final product is determined by the position of a bulk 
residue within the active pocket, as the “molecular ruler” (65, 68) (Figure 6b). In E-
prenyltransferases, a bulk residue located before the first DDxxD motif forms the floor 
of the pocket. Enzymes that give different product lengths usually have a bulky residue 
at different positions. For example, FPP synthase has a phenylalanine at the fifth position 
before its first DDXXD motif, which prevents the formation of products longer than 
fifteen carbons (66). The heptaprenyl pyrophosphate synthase has an isoleucine located 
at the eighth position before its first DDXXD motif, which therefore produces a longer 
product with 35 carbons (69).  
           Protein prenyltransferases is another class of prenyltransferase and transfers a 
polyprenyl moiety (FPP or GGPP) to the thiolate group of a cysteine residue within the 
CAAX motif of the target protein (70). Ras farnesyltransferase (Ras FTase) is one 
example. It transfers a farnesyl moiety to the protein Ras, a small G-protein that is 
important for signal transduction and carcinogenesis. As the farnesylation of Ras is 
essential for its function, inhibitors against Ras FTase have shown inhibition against 
tumor cell growth and may possess the potential to be developed into anti-tumor drugs 
(71). 
Cyclization 
           Most terpenoids are polycyclic, produced by cyclization of linear polyprenyl 
diphosphates, which involves three steps (48): i) the creation of a carbocation; ii) the 
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rearrangement of the carbocation to create the prototype of the product; iii) the 
quenching of the carbocation. Cyclases use different strategies to complete each step. 
For example, the carbocation can be created by releasing the pyrophosphate group, 
protonation of a double bond or protonation of an epoxide. It is generally quenched by 
deprotonation and formation of a double bond. The product diversity is usually 
determined by how the substrate folds in the active pocket, rearrangement of the 
carbocation and the final location where the cabocation is quenched. In cyclases, 
catalytic residues are aligned in a particular manner that one type of carbocation 
intermediate is stabilized (72, 73). 
           One example for cyclization is the synthesis of steroids. Steroids are a family of 
chemicals that share a common core structure, composed of four rings (three 6-member 
rings and one 5-member ring). Cholesterol is the most important member of this family. 
It is an essential component of eukaryotic membranes and also plays important roles in 
the development of cardiovescular diseases. In bacterial, hopenes (with four 6-member 
rings and one 5-member ring) are produced instead of steroids. Squalene is the precursor 
of both steroids and hopenes. In bacteria, squalene-hopene cyclase initiates the 
cyclization by protonating the C2-C3 double bond of squalene and creating a 
carbocation (74). In eukaryotes, squalene monooxygenase first oxygenates the C2-C3 
double bond, creating 2, 3-oxidosqualene. The protonation of the 2, 3-epoxide creates 
the carbocation and initiates the cyclization, which is catalyzed by lanosterol synthase 
(74). The bacteria squalene-hopene cyclase has been well studied (74, 75). The crystal 
structure shows that it is a homodimers with three cavities: two small water-filled 
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cavities and one large hydrophobic centre cavity. The substrate binds to the centre cavity. 
Conserved residues aligned around these cavities contribute catalysis by stabilizing 
carbocations intermediates at various stages. Mutations on these residues will produce 
alternative products with fewer rings, which indicate the premature quenching of the 
carbocation (74).  
MVK 
Enzymatic properties 
           MVK catalyzes the phosphorylation of mevalonate to phosphomevalonate. 
Enzymes from mammalian, bacterial and archaea sources have been characterized (76, 
77, 78, 79). The size of MVK is around 40 KD. Size-exclusion chromatography 
indicated it mostly forms a homodimer in solution (76, 77, 79). In E. faecalis, however, 
MVK exists predominantly as a monomer (78).  
           The ordered sequential reaction mechanism of MVK was established by a series 
of studies in the hog enzyme (80). Product MgADP has been shown competing with 
ATP. The second product, 5-phosphomevalonate, was found to be a noncompetitive 
inhibitor when either MgATP or mevalonate is the variable substrate. The product 
inhibition pattern, combined with studies on terpenoid inhibition (81), suggested that 
mevalonate is the first substrate to bind and mevalonate-5’-phosphate is the first product 
to be released (Figure 7). 
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Figure 7 The Reaction Mechanism of MVK. 
E is MVK, A is mevalonate, B is ATP, P is 5-phosphomevalonate and Q is ADP. 
 
           The activity of MVK is dependent on divalent cations. Mg2+, Mn2+, Zn2+, Ca2+ 
and Co2+ were found to support the enzyme activity (80). Studies on hog enzymes 
showed that when metal ion concentration was lower than 1 mM, Mn2+ was the best 
activator. Mg2+ was found to show the best stimulatory effect when the concentration 
was higher then 10 mM. Enzyme activity was also stimulated by reducing agent. 1 mM 
dithiothreitol or 10 mM β-mercaptoethanol was sufficient to prevent the loss of activity 
by oxidation. It was also found that the addition of thiol group binding agents, such as p-
hydroxymercuribenzoate, inhibited the enzyme. These data suggested that there is an 
important cysteine residue involved in enzyme activity (80).  
           Although ATP is probably the preferred phosphoryl donor, as demonstrated by 
studies in the yeast enzyme (81), alternative nucleotides, such as ITP, GTP, CTP and 
UTP, are also used by MVK. Studies in the E. faecalis enzyme suggested that the Km 
values for all four nucleotides are similar (78). The hog enzyme, however, was reported 
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to only use ATP and IPP as phosphoryl donors (82). Therefore, MVKs from different 
species seem to have a degree of variability in the selectivity of nucleotides.   
           MVK is also inhibited by downstream terpenoid products, such as GPP, FPP, 
GGPP, dolichol monophosphate, etc (81, 83). Terpenoids are competitive with ATP and 
uncompetitive with mevalonate. This probably suggests a feedback control mechanism 
at the post-translational level.  A recent study also showed that pyrophosphomevalonate, 
the product of phosphomevalonate kinase, inhibits the S. pneumoniae enzyme as a 
noncompetitive inhibitor (84). This compound does not inhibit the human enzyme, 
which suggests that it may be developed into an anti-bacteria agent.  
General mechanisms for phosphoryl transfer 
           Most kinases form a ternary complex in which the phosphoryl donor and acceptor 
are in the “in-line” geometry. Therefore, the transfer of the phosphoryl group takes place 
directly between two substrates and the reaction mechanism is sequential (85). The exact 
mode for phosphoryl transfer is still subject to debate. Two possibilities have been 
proposed. In the associative mechanism (SN2), a pentagonal bipyrimidal transition state 
is formed at the γ-phosphorus. Both the phosphoryl acceptor (the nucleophile) and the 
leaving group (ADP) are at the apical positions, while the other three γ-phosphate 
oxygens are in the equatorial positions (86). In the dissociative transition state (SN1), the 
bond between the β- and γ-phosphate breaks first to produce a trigonal planar 
metaphosphate transition state that is then captured by the phosphoryl acceptor (86). 
Experimental evidence so far is not conclusive for either of the mechanisms (86).  
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           Almost all kinases need metals, mostly Mg2+, for catalysis. Generally, Mg2+ is 
coordinated by the β- and γ- or the α-, β-, and γ-phosphate groups, as well as protein 
residues and ordered water molecules. The coordination of Mg2+ polarizes the bond 
between the β- and γ-phosphate and makes the γ-phosphorus atom more electrophilic 
(86). It also orients the γ-phosphate so it is “in-line” with the phosphoryl acceptor as 
required by the reaction (86, 87). Kinases also use several mechanisms to stabilize the 
transition state (86). In both the P-loop kinases and GHMP kinases, the γ-phosphate 
group is located in adjacent with the positive charged N-terminus of an α-helix, which 
may neutralize the negative charges accumulated on the γ-phosphorus during the 
phosphoryl transfer (86, 88). A conserved positively charged residue (e. g. lysine) is 
often found near the β- and γ-phosphate groups, which may play a similar role (86, 88).   
Catalytic basis of MVK 
           Since this dissertation is partly focused on MVK, its catalytic mechanism is 
investigated in this study and will be discussed in detail in the following chapter. Here 
only a brief review on this subject is presented.  
           Mutagenesis studies on MVKs, particularly those from the human and rat, 
established the basis for catalysis. Although many conserved residues have been found 
involved in the enzyme activity, two are most prominent based on the profound activity 
deficiency caused by their mutations. The first one is a fully conserved aspartate residue 
(Asp 204 in the human protein). Mutation of this residue to either an asparagine or 
alanine decreases Vm for more than 10,000 fold (89). As will be discussed later, a 
general base is used in MVK as the catalytic residue. Therefore, this conserved aspartate 
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residue has been suggested to play this role. The other one is the second serine residue in 
the invariant GLGSSA motif (equivalent to Ser 146 in the human enzyme). Its mutation 
to an alanine decreases Vmax for more than 1000 fold and also weakens the binding of 
Mg2+-ATP (90). This residue was suggested as a potential ligand for Mg2+. 
Regulation and cellular localization of MVK 
           In addition to the feedback control by terpenoids, MVK is regulated at the 
transcriptional level, coordinated with HMG-CoA reductase. For example, diets with 
lovastatin (an statin class HMG-CoA reductase inhibitor) causes the level of MVK 
protein and mRNA to increase, while diets supplemented with 5% cholesterol causes 
both protein and mRNA level to decrease (91). The basis for transcriptional regulation is 
in the promoter region containing two Sp1-binding sites and one SRE. SRE also exist in 
the genes of HMG-CoA reducatase and LDL receptor, indicating it as a major regulatory 
element in response to the sterol level (91). The fact that MVK is regulated both 
transcriptionally and post-translationally suggests this enzyme is a regulatory point, 
second to HMG-CoA reductase, in the mevalonate dependent IPP biosynthesis.  
           Studies in the hog and rat MVK suggest that this enzyme is located in the 
peroxisomes. This organelle also contains other enzymes involved in terpenoids 
biosynthesis, including HMG-CoA reductase, HMG-CoA synthase, acetoacetyl-CoA 
thiolase, phosphomevalonate kinase, pyrophosphomevalonate decarboxylase and FPP 
synthase, indicating the compartmentation of the terpenoid biosynthesis, in particular the 
mevalonate dependent pathway, in the peroxisome (92). 
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Deficiency of MVK  
           Mutations in MVK cause deficiency in IPP biosynthesis, which leads to diseases 
with the symptom varied from mild to life-threatening (91, 93, 94, 95). Mevalonic 
aciduria is caused by the total loss of MVK activity. Patients with mevalonic aciduria 
have pychomoter retardation, hypotonia, ataxia, recurrent episode of fever and even 
development delay, cataracts and diarrhea. The victims of the most severe form of 
mevalonic aciduria often die early in infancy. A much more benign symptom is HIDS. 
HIDS patients mainly suffer from episodes of fever, but lack the more serious 
developmental problems.   
           Mutations that cause these diseases have been mapped onto MVK gene. One of 
the most common mutations is V377I, as the cause for many HIDS cases (91). 
Interestingly, protein that carries this mutation shows about 35% residue activity when 
being expressed in E. coli but there are almost no detectable MVK proteins in fibroblasts 
from the patient, which probably suggests that this mutation mainly affects the protein 
stability in vivo (91). Other mutations include H20P, T243I, I268T, A334T, etc (91, 94, 
95).  
           What is the mechanism for these mutations to cause the disease? The recent 
published rat MVK crystal structure provides some clues to this question (96). Residues 
His 20 and Ala 334 are located within the active site and their mutations probably 
directly disrupt catalysis or substrate binding. Residue I268 is in a helix that is involved 
in dimer formation. Probably its mutation will disrupt the dimer and makes the protein 
less stable. More interesting is the residue Val 377. It is far from the active site and does 
 47
not have any apparent role in protein dimerization. Modeling an isoleucine into its 
position does not generate any clash with neighboring residues (96). Therefore, it is still 
unclear how this mutation decreases the stability of the protein.  
Significance of This Work  
           MVK is a key enzyme in the terpenoid biosynthesis and an important regulatory 
point in the mevalonate dependent pathway. Its importance has been demonstrated by 
the diseases caused by its mutation. It has also been shown that MVK is indispensable 
for the growth of many gram positive bacteria (52), indicating it could be a target for 
drug designing. To study MVK, we expect to understand the structural basis for its 
substrate binding, catalysis and inhibition. We would also like to compare its structure 
with other members of the GHMP family in order to delineate the structural conservation 
and variation within this family. In the next chapter, we will present a study of the M. 
jannaschii MVK that analyzes this enzyme from both structural and biochemical 
perspectives. Our results shed light on the structural mechanism of this important 
enzyme.  
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CHAPTER III 
STRUCTURAL STUDY OF MVK   
Methods 
Protein expression and purification  
           The gene for the M. jannaschii MVK was initially cloned into the pET28a vector 
with an N terminal his-tag and a T7 promoter. The construct was provided by our 
collaborator A I. Scott (76) and was used to transform B834(DE3) E. coli strain.  Cells 
were grown in LB media containing 100 µg/ml kanamycin at 37˚C until OD600 was 
around 0.8 when the gene expression was induced by IPTG at 1 mM concentration. Cells 
were then grown at 18˚C for 20 hours, harvested and frozen at -20˚C.   
           In order to perform a MAD experiment, the selenomethionine substituted protein 
was produced. Cells were grown in LB media containing 100 µg/ml kanamycin at 37˚C 
until OD600 was around 0.8. Cells were harvested, washed with M9 minimal media (with 
100 µg/ml kanamycin and 50 µg/ml 19 amino acids except methionine) twice, and then 
grown in this media for 1 hour at 37˚C. Selenomethionine and IPTG were then added at 
50 µg/ml and 1 mM concentration, respectively. After this step, the procedure was the 
same as the native protein production.  
           To purify the protein, cell pellets were thawed and re-suspended in 20 mM Tris-
HCl (pH 7.5), 500 mM NaCl, 1 mM PMSF, 20 mM immidazole and lysed with a French 
press. The addition of PMSF is mandatory, because MVK has the tendency to be cleaved 
by proteases into two fragments (about 28 KDa and 7 KDa, respectively). Since M. 
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jannaschii MVK is a thermostable protein, with optimal activity at around 70 ˚C, the 
cell extract was heated to this temperature for 15 minutes, which denatured most E. coli 
proteins but fully retained MVK activity (76). After centrifugation at 16,000 G for 30 
minutes, the supernatant was passed through a 0.45 µm filter and then applied to a nickel 
affinity column (AP Biotech) that was eluted with an imidazole gradient. MVK was 
eluted from the column when imidazole concentration reached 180 mM. Fractions were 
checked with SDS-PAGE and showed a major band with purity level estimated to be 
above 95%. Its position is consistent with the predicted molecular weight of the His-
tagged MVK (37340 Da). Fractions with MVK were pooled and dialyzed with the 
protein storage buffer (5mM Tris, 1mM DTT, pH 7.5). Finally, MVK was concentrated 
to around 15mg/ml and stored at -20 ˚C.  MVK shows stable activity for at least one 
year under this storage condition. The yield of MVK is about 10 mg protein per liter 
culture.          
Assay of MVK activity  
           (RS)-mevalonate was initially purchased as mevalonic acid lactone. To prepare a 
stock solution with 50 mM of mevalonate, 65 mg mevalonic acid lactone was dissolved 
in 3 M KOH and heated to 37 ºC for 1 hour to completely hydrolyze the lactone. The pH 
was then adjusted to 7.0 by 0.2 M HCl and the final volume was 10 ml. A PK/LDH 
coupling assay system was used to measure MVK activity. The measurement was 
performed in a Cary 100 spectrometer.  To measure the Km of ATP, a reaction was 
performed in a 0.5 ml quazi cuvette containing 0.1 M KH2PO4/K2HPO4 buffer (pH 8.0), 
250 µM NADH, 1 mM phosphoenol pyruvate, 5 mM MgCl2, 2.5 mM (RS)-mevalonate, 
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40 unit PK and 37.5 unit LDH, 0.55 µg MVK and 10 µM to 500 µM ATP. The 
background oxidation of NADH was monitored at 340 nm for 2 minutes before the 
reaction was initiated by the addition of MVK. The reaction was followed at 340 nm for 
anther 2 minutes and the slope was recorded as the initial velocity. To measure the Km of 
(RS)-mevalonate, 2.5 mM ATP and 10 µM to 500 µM (RS)-mevalonate was used 
instead. To test MVK activities on alternative nucleotides, 500 µM of GTP, CTP or UTP 
as well as 400 unit of PK were used in each reaction.  
           In order to measure the inhibition by putative inhibitors, 0.55 µg of MVK was 
first incubated with 40 nM to 200 µM of the inhibitor on ice for 5 minutes. The mixture 
was then added into the cuvette that contains all other assay components mentioned 
above. (RS)-mevalonate concentration was fixed at 2.5 mM. ATP concentration was 
fixed at 500 µM during the measurement of the IC50 and varied from 10 µM to 500 µM 
when global curve fitting method (see below) was used to determine the Ki (for ADPβS). 
To validate the hits from virtual screening, compounds were first solubilized in DMSO 
to make 1 mM stock solutions. During the reaction, 5 µl of the stock solution was 
included into the 0.5 ml reaction. For the blank, a reaction with 1% DMSO was 
performed. To rule out the possible inhibition to coupling enzymes, a 0.5 ml reaction 
containing 0.1 M KH2PO4/K2HPO4 buffer (pH 8.0), 250 µM NADH, 1 mM phosphoenol 
pyruvate, 5 mM MgCl2, 0.073 unit pyruvate kinase, 37.5 unit lactate dehydrogenase, 50 
nM ADP and 10 µM inhibitors was performed.  
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Determination of kinetic values 
           The IC50 of terpenoid inhibitors was determined by measuring reaction velocity 
under the inhibitor concentration at a range of 200 µM to 40 nM. The data were fit using 
following equation, with the non-linear regression program Kaleidgraph: 
                                                   V = T/(1+[I]/IC50)                                                       (3. 1) 
where [I] is the inhibitor’s concentration; V is the initial velocity; T is the top plateau for 
the curve. Since terpenoids are competitive inhibitors against ATP, their inhibition 
constant Ki can be calculated from IC50 values using the following equation: 
                 Ki = IC50/(1+Km/[ATP])                                                                               (3. 2) 
where Km is the Michaelis constant for ATP, while [ATP] is the concentration of ATP.  
           Km values for ATP and mevalonate were determined by plotting the initial 
velocity with the substrate concentration. The data were fit with the Michaelis-Menten 
equation: 
                 V= Vm [S]/(Km+[S])                                                                                     (3. 3) 
where Vm is the maximal velocity and [S] is the concentration of the substrate that varies. 
           The inhibition of ADPβS was studied by performing the reaction under various 
concentrations of ADPβS, as described above. The nature of competitive inhibition was 
revealed by the Lineweaver and Burk plot. The inhibition constant Ki was determined 
with global curve fitting in the program GraphPad Prism, using the following equation: 
                    V= Vm[ATP]/(Km+[I]Km/Ki+[ATP]).                                                       (3. 4) 
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Crystallization  
           Crystallization was accomplished by the hanging drop vapor diffusion method. 
MVK apoprotein crystals were grown by mixing 2 µl of the His-tagged protein with an 
equal volume of the reservoir solution and equilibrating against a 400 µl reservoir. The 
crystallization condition contains 28 to 30% dioxane, 20 mM to 50 mM imidazole and 
10 mM DTT. To improve the crystal quality, seeding was performed by transferring 
preformed crystals into new drops with the crystallization condition of 22% to 26% 
dioxane, 20 mM imidazole, 10 mM DTT and 10 mM MgCl2. To produce crystals 
complexed with the nucleotide ligand, MVK was first incubated with 10 mM MgCl2, 10 
mM DTT, 0.5 to 2 mM nucleotide ligand and 2.5 mM mevalonate and then used for 
setting up the crystallization experiment, as described above. Apoprotein crystals were 
seeded into these drops. To produce MVK crystals complexed with terpenoid ligands, 
terpenoids stock solutions (about 2 mM concentration, in ethanol, as purchased from 
Sigma) were first dried in a SpeedVac low vacuum system and then resuspended to 20 
mM in aqueous solution containing 0.6% n-octyl-β-D-glucopyranoside and 5 mM tris 
(pH 7.5). MVK was then incubated with 1.5 mM terpenoids, 10 mM DTT and 2.5 mM 
mevalonate. Crystals were grown using the seeding method, as described above, except 
that 10 mM EDTA instead of MgCl2 was used in the crystallization condition, to prevent 
terpenoids from being precipitated by MgCl2. The details of developing the seeding 
protocol will be discussed in the result section. 
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Crystallographic methods 
           Data were collected at 121 K. Cryoprotectant was prepared by mixing 2.5 µl 
MPD with 7.5 µl crystallization solution taken from the same reservoir well. The MAD 
experiment with a selenomethionine substituted apoprotein crystal was performed at the 
beamline 14BMD at APS in Argonne National Laboratory. The selenium absorption 
edge was first determined to be at 12.6618 Kev by fluorescence scanning of the crystal. 
A four-wavelength dataset (peak: 0.9792 Å; inflection: 0.9794 Å; high-energy remote: 
0.9611 Å and low-energy remote: 0.9919 Å) was collected from that crystal with one-
degree oscillation widths through a range of 360° for each wavelength (Table 2). Data 
for ligand bound crystals were collected at beamlines 14BMD, 14BMC, 19ID, 19BMD 
at APS and the protein crystallography beam line at CAMD. One-degree oscillation 
widths were collected through a range of 180° or when 95% completeness was reached 
(Table 3).  
           Data were processed using HKL2000. All crystals belong to the primitive 
monoclinic space group P21 with similar cell dimensions, though a 3 Å reduction in the 
a axis is present in the ADPβS crystal. Matthews coefficient (97) calculation suggested 
only one molecule per asymmetric unit with the specific volume 2.2 Å3/Da. The solvent 
fraction is about 0.43. The apoprotein structure was determined in program SOLVE, 
followed by phase improvement with RESOLVE. The model was manually built in 
program SPOCK and O. The structure was refined in CNS. To determine the ligand 
bound crystals structures, the apoprotein structure was used as the model for refinement 
against the diffraction data in CNS or REFMAC. Phases were improved by the bias 
 54
removal program Shake ‘n’ wARP and the model was rebuilt in program XtalView and 
refined in CNS or REFMAC. The structure was validated by PROCHECK (98).   
 
 
Table 2 Data Collection Statistics of the MAD Experiment. 
 
Rsym = ΣhklΣi|Ii (hkl)  I(hkl) |/Σ hklΣiIi (hkl), where Ii (hkl) is the intensity of  an 
individual observation and I(hkl)  is the mean intensity of reflection (hkl). 
 Peak  Inflection 
High Energy 
Remote 
Low Energy 
Remote 
Space Group P2(1) P2(1) P2(1) P2(1) 
Cell Dimensions 
a, b, c (Å) 
α, β, γ (º) 
56.14, 44.03, 64.85 
90, 102.71, 90 
56.14, 44.03, 64.86 
90, 102.71, 90 
56.14, 44.03, 64.85 
90, 102.71, 90 
56.16, 44.05, 64.86 
90,102.71,90 
Wavelength (Å) 0.9792 0.9794 0.9611 0.9919 
Resolution (Å) 2.4 2.4 2.4 2.4 
Rsym   0.063(0.126)  0.068(0.122)  0.061(0.126)  0.062(0.111) 
I/σ(I) 20.9(6.5) 18.6(5.2) 21.2(6.7) 21.2(6.7) 
Completeness (%) 94.5(72.1) 87.1(47.8) 96.2(79.2) 94.7(69.2) 
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Table 3 Statistics of Data Collection and Structural Refinement.
 MVK-AMPPCP-Mg2+ MVK-UTP-Mg2+ MVK-ADPßS-Mg2+ MVK-ADP-Mg2+
                          Data Collection     
Space Group                         P2(1)                  P2(1)                    P2(1)                      P2(1)
Unit Cell Parameters 
a, b, c (Å ) 
a, ß, γ (º) 
  55.887, 43.971, 64.446
       90.0, 102.357, 90.0
 
55.849, 43.806, 65.081 
     90.0, 102.638, 90.0 
52.777, 43.847, 66.249
     90.0, 102.471, 90.0
 55.998, 43.900, 65.020
          90.0, 102.41, 90.0
Wavelength (Å ) 0.9795 0.9793 1.3776 0.9789
Resolution Range (Å )                       50.0-1.71                     50.0-1.75                     50.0-2.12                        50.0-2.44
Rsym                 0.045 (0.587)               0.046 (0.316)                 0.106(0.564)                    0.051(0.173)
Completeness (%)                     99.6 (98.3)                    97.9(90.3)                    71.9(28.0)                       99.4(95.3)
I/σ(I)                       30.5(2.6)                      37.9(3.9)                      10.4(0.6)                         28.1(9.2)
Refinement     
No. of Atoms/Residues 
Protein 
Ligand 
Metal 
Water 
317
1
1
114
 
317 
1 
1 
172 
317
1
1
42
317
1
1
95
Maximum Resolution (Å) 2.00 2.00 2.30 2.44
Rwork 0.204 0.193 0.215 0.219
Rfree 0.251 0.248 0.282 0.267
Average B factor (Å2) 26.5 23.4 50.8 27.2
r.m.s.d from Ideal Geometry 
Bond Distance (Å) 
Bond Angles (Å) 
 
                                 0.0095
1.57
 
0.011 
1.77 
0.010
1.53
0.019
1.68
Ramachandran Plot (%) 
Favored 
Allowed 
Generously Allowed 
Disallowed 
                                     92.0
7.3
0.7
0.0
 
92.3 
7.0 
0.3 
0.3 
87.1
                                   12.5 
0.3
0.0
91.3
7.7
1.0
0.0
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Methods for virtual screening 
           For the FLEXX docking, compound databases were downloaded from the 
Maybridge, NCI and ZINC websites. Docking was performed on four processors of SGI 
MIPS R12000 via the SYBYL7.0 graphic interface. For LUDI docking, the program as 
well as the library was accessible through INSIGHT. The active site for docking purpose 
was created by drawing a sphere around either the carbon atom between β and γ 
phosphorus of the AMPPCP ligand or the Ca atom of Ser 112, with a radius of 15Å. This 
covers the entire ATP binding site, as well as the potential mevalonate binding site.  
           The criteria for compound extraction were primarily based on docking scores (the 
FLEXX or LUDI scores). Compound scored within top 1% were extracted. Consensus 
scores, if available, were also considered. To determine the consensus score (CScore), 
docking scores were first calculated for each docked pose with several scoring functions 
during the docking process in FLEXX. The consensus among these functions was then 
evaluated in SYBYL. Compounds were excluded from visual inspection if their CScores 
were lower than 3 and from in vitro testing if they were lower than 4 (except for 
compound SPB01501). Visual inspection evaluated the binding modes and structures of 
docked compounds. In general, only one compound from those with similar the 
structures and docking scores was selected for validation.  
Results and Discussion 
Sequence analysis  
           MVK sequences from different species were studied by multiple sequence 
alignment, which revealed several strictly conserved residues (Figure 8). Mutation 
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studies had already shown that some of these residues, such as Glu 19, Ser 145, Ser 146, 
Glu 193, Asp 204 and Ala 334 (99) in the human enzyme and Lys 13 (100) in the rat 
enzyme are important for the enzyme activity. Among them, D204A decreases the Vm 
nearly10,000-fold.  In the M. jannaschii MVK, Glu 14, Ser 111, Ser 112, Glu 144, Asp 
155, Ala 276 and Lys 8 are equivalent to the above conserved residues in the human and 
rat proteins, respectively. These results help to establish the probable mechanism of the 
enzyme and facilitate our structural analysis of the active site cavity. 
           Three motifs, designated as motif I, II and III, have been identified (76). They are 
also conserved among other GHMP proteins (101). Motif I is close to the N- terminus of 
the protein, including the residues from Pro 6 to His 15 in the M. jannaschii enzyme. It 
has the sequence PXKXIXXGEH. Motif II corresponds to the region between Pro 104 to 
Ser 114 of the M. jannaschii protein with an invariant GLGSSA sequence and is 
generally recognized as the signature motif for GHMP kinases. It forms the phosphate-
binding loop. Motif III is characterized by residues Lys 272 to Cys 281 of the M. 
jannaschii protein and contains an invariant sequence TGAGGGG.  
Seeding improves the quality of MVK crystals 
           The MVK apoprotein crystals which formed directly were either tiny single 
crystals (less than 0.05 mm) or larger multiple crystals that were unsuitable for 
diffraction. Optimization trials by grid or additive screens did not improve the crystal. A 
seeding protocol was then tried by introducing preformed crystals into a new drop. 
Interestingly, massive nucleation was triggered as a result and a large number of small 
single crystals were observed. Therefore, we decided to focus on decreasing the  
  
58
 
 
 
Figure 8 Multiple Sequence Alignment of MVKs from Various Sources. 
 
Three conserved motifs are highlighted. The important residues are marked by asterisks. Sequences 
are color coded as blue (invariant), cyan (identical residues) and magenta (similar residues). 
Organisms in which these sequences are generated are coded as follows: Mt (Methanobacterium 
thermoautotrophicum), Pa (Pyrococcus abyssi), Mj (Methanococcus jannaschii), Hs (Homo sapiens), 
Rn (Rattus norvegicus), At (Arabidopsis thaliana), Sp (Schizosaccharomyces pombe) and Sc 
(Saccharomyces cerevisiae). 
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Figure 8 Continued. 
 
 
nucleation. During the previous optimization process, Mg2+ was found to prevent crystal 
growth. Therefore, 10 mM MgCl2 was included in the drop in which the seeds were to 
be transplanted. The dioxane concentration in the new drop was also lowered to between 
22% and 26%. The nucleation did decrease and the fewer crystals grown from the seeds 
were much bigger (typically more than 0.1 mm). Diffraction test indicated that these 
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crystals diffracted to 3 to 4 Å using our home X-ray source. Their quality was 
independent of the morphology of the seeded crystal, which can be rationalized that they 
were actually grown out of invisible nuclei, probably released from the trunk of the 
seeded crystal as they underwent disintegration in the new crystallization drop. Basically 
this procedure can be regarded as a simplified form of the microseeding. 
           Having been incubated with the ligand, MVK seemed to have a lower propensity 
to crystallize. Therefore, we developed a heterogeneous seeding protocol by 
transplanting apoprotein crystals into drops containing MVK incubated with ligands. 
Compared with apoprotein crystals, crystals complexed with ligands were generally 
smaller (less than 0.1 mm) and more likely to be plane-like. Nevertheless, they had good 
diffraction quality at synchrotron radiation sources.   
Apoprotein structural solution 
          The M. jannaschii HSK has about 20% sequence identity with the M. jannaschii 
MVK. The PDB coordinates of the HSK were downloaded from the protein data bank 
and used as the model for molecular replacement trial to solve the MVK structure, 
before we could collect the MAD dataset. Solutions from both rotational and 
translational search steps only had a low ratio for signal over noise, which indicated the 
failure of molecular replacement. After solving the MVK structure by MAD technique, 
it was found that the relative orientations between the N- and C-domain in MVK and 
HSK are apparently different, which probably makes HSK an unsuitable model.   
           The MAD data were first checked for the presence of anomalous scatters by 
calculating an anomalous difference Patterson map based on the peak dataset. Peaks due 
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to the presence of anomalous scatterers can be identified on the Harker section (y=0.5) 
(Figure 9).  MAD phasing in SOLVE, using four wavelength data at the resolution range 
from 20 to 2.4 Å, located all six selenium sites in one asymmetric unit. The overall 
figure of merit is 0.65. The statistics of heavy atom sites indicate that the structural 
solution is correct (Table 4). The protein phases were improved with the electron density 
modification program RESOLVE. The map generated with the RESOLVE modified 
phases was less noisy. Furthermore, the density for protein chains was improved 
significantly. For example, the region around the loop Val 191 to Glu 194 was not well 
resolved in the map before density modification (Figure 10a). There was a break 
between residues Ala 193 and Glu 194. In addition, the side chain of Tyr 192 was 
largely missing. After the density modification, these problems were corrected (Figure 
10b).  The modified map was used for all subsequent model building. 
           Model refinement was performed in CNS, after up to 70% of residues were built. 
The first several rounds of refinement were simulated annealing, in which molecular 
dynamics in torsion angles were applied with a starting temperature of 2500 K. The 
model building process was alternated with the simulated annealing process, until the 
model building was complete, when the R factor was about 0.35 and Rfree factor about 
0.44. Further rounds of refinement, including minimization and individual B factor 
refinement, brought these two R factors to about 0.30 and 0.35, respectively. Water 
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Figure 9 Anomalous Patterson Map. 
 
Shown is the Harker section (y=0.5) of the anomalous difference Patterson map 
based on the peak data set. The map was calculated by xfft in XtalView. The 
resolution range used for calculation is from 3 to 6Å and the outlier filter was set at 
30% of average. The first contour level is at 3σ and each contour line thereafter 
represents 1σ in peak intensity.  
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Table 4 Selenium Sites and Their Statistics. 
 
FOM is the mean value of the cosine of the error in phase angles.  
Height/Sigma is the peak height from the cross-validation of the difference Fourier.  
X Y Z Occupancy B Factor Height/Sigma 
0.431 0.006 0.251 0.912 24.7 17.8 
0.419 0.083 0.126 0.927 33.8 15.2 
0.458 0.028 0.423 0.926 60.0 10.9 
0.639 0.486 0.349 0.802 60.0 9.0 
0.472 0.932 0.295 0.745 27.5 14.1 
0.043 0.785 0.381 0.381 28.9 7.9 
FOM 0.65    
Overall Z Score 30.79    
 
 
 
 
molecules were then added by the automatic water picking method in CNS and 
individual occupancies of water molecules were then refined, in combination with more 
model rebuilding and structural minimization, which gradually brought the R factor 
down to about 0.22 and Rfree to about 0.30. Two more additional densities were 
identified as dioxane molecules, the precipitant for crystallization, and were fit 
accordingly. Their group occupancies were refined to 1.06 and 0.78, respectively. 
Finally, the weighting factors for X-ray term weight (Wa) and for B factor refinement 
were also optimized. Final rounds of refinement using optimized weighting factors 
produced a structure with the R factor 0.20 and Rfree factor 0.28 (Table 5). 
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Figure 10 The Electron Density Maps before and after Density Modification. 
 
a. The Electron Density Map (Contoured at 1σ) Based on Phases Generated by 
SOLVE 
 
b. The Electron Density Map (Contoured at 1σ) Based on SOLVE Phases Improved 
by RESOLVE 
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Table 5 Refinement Statistics of MVK Apoprotein Crystal Structure. 
 
No. of Residues  
Protein 317
Water 92
Dioxane 2
Rwork 0.197
Rfree 0.282
Average B factor (Å2) 32.5
   r.m.s.d from Ideal Geometry 
Bond Distance (Å) 
Bond Angles (º) 
0.012
1.622
Ramachandran Plot (%) 
Favored 
Allowed 
Generously Allowed 
Disallowed 
88.5
10.8
0.7
0.0
 
 
 
Overall structure of the apoprotein 
           Similar to other GHMP kinases, the MVK monomer is a dumbbell-shaped 
molecule and contains two structural domains. Its size is about 60×30×25 Å (102). At 
the domain interface there is a cleft with the dimension about 30×15 Å, where the active 
site is located (Figure 11a). The secondary structural elements in this protein are listed in 
Table 6.  
           A DALI search (103) has been performed to investigate structural homologs of 
MVK. The top hits include the rat MVK (1KVK Z-score 32.5), galactokinase (1S4E Z-
score 30.7), phosphomevalonate kinase (1K47 Z-score 28.4), HSK (1FWK Z-score 26.1), 
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CDP-ME kinase (1UEK Z-score 21.1), C. elegans sexual determinant Xol-1 (1MG7 Z-
score 16.9), mevalonate 5-diphosphate decarboxylase (1FI4 Z-score 15.9).  They all 
belong to the GHMP kinase family. With the structural superposition program TOPP  
 
 
 
 
Figure 11 Rat and M. jannaschii MVK. 
 
a.  Structure of the M. jannaschii MVK  
 
b.  Structural Alignment of the Rat (golden) and M. jannaschii (cyan) MVK    
 
(104), the structure of MVK has been aligned with CDP-ME kinase (173 residues match 
and r.m.s.d of 1.77 Å), homoserine kinase (191 residues match and r.m.s.d of 1.96 Å), 
phosphomevalonate kinase (174 residues match and r.m.s.d of 1.93 Å) and galactokinase 
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(204 residues match and r.m.s.d 1.63 Å). The structural similarity indicates the 
conservation among GHMP kinases.    
           The quality of the structure was checked with the program PROCHECK. From 
the Ramachandran plot, the geometry of the structure is good, with 88% non-glycine 
residues in the most favorable region (Figure 12). Notably, for a typical protein structure,   
 
Table 6 List of MVK Secondary Structural Elements. 
 
α-Helices Residues 
A 70 to 87 
B 110 to 127 
C 132 to 148 
D 154 to 162 
E 176 to 185 
F 200 to 208 
G 213 to 230 
H 232 to 250 
I 254 to 268 
J 287 to 300 
β-Strands Residues 
a 1 to 12 
b 23 to 38 
c 42 to 49 
d 52 to 58 
e 95 to 101 
f 163 to 168 
g 170 to 175 
h 188 to 195 
i 269 to 274 
j 280 to 285 
k 303 to 309 
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Figure 12 Ramachandran Plot of MVK Crystal Structure. 
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about 78.2% of the residues are in the most favorable region.  The other parameters are 
also comparable or better than the typical crystal structure at this resolution level. 
Fold analysis 
           The N-domain can be identified as a “ribosomal protein S5 domain 2–like” fold 
and probably originated from a nucleic acid binding protein. One feature of this domain 
is a highly conserved phosphate-binding loop, composed of a long loop and the N-
terminus of an α-helix (the helix B), as the site for the nucleotide binding, which is 
shared among all GHMP kinases. The other feature of this domain is a large mixed five-
stranded β-sheet (formed by strands a, b, c, d, e) and a smaller anti-parallel four-
stranded β-sheet (formed by strands a, b, f, g) at one side packed with four long α 
helices (helices A, B, C and D) at the other side. (Figure 13a)  
           The structure of this N-domain was compared with that domain in other GHMP 
kinases (Figure 13a, b, c, d, e, f). Most part of the N-domain seems to be conserved. 
However, there are substantial differences around the region equivalent to the β strand d 
in MVK. HSK and CDP-ME kinase do not have this strand. Instead, in these two 
proteins, the element corresponding to the strand c of MVK immediately connects to the 
next helix (equivalent to the helix A in MVK) by a short loop (Figure 13b, c). 
Mevalonate 5-diphosphate decarboxylase lacks the equivalent the strand d and its overall 
structure shows more deviation from the rest of the GHMP kinases (Figure 13f).    
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Figure 13 Fold Comparison of N-domains of GHMP Kinases. 
 
N-domains from MVK (a), HSK (b), CDP-ME kinase (c), galactokinase (d), 
phosphomevalonate kinase (e) and mevalonate 5-diphosphate decarboxylase (f) are 
shown. The secondary structural elements in MVK are labeled. Regions where 
major structural deviation takes place are marked by arrows.  
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           The C-domain is composed of a conserved structural core that adopts a βαββαβ 
fold, formed with a four-strand anti-parallel β-sheet (strands h, i, j, k) packed with two 
α helices (helices I and J).  There are three additional helices (helices F, G and H) that   
are considered to be an insertion between the strand h and the helix I (Figure 14a). The 
structure of the insertion is more variable in each member of the GHMP kinases family  
 
 
 
Figure 14 Fold Comparison of C-domains of GHMP Kinases. 
 
C-domains from MVK (a), HSK (b), CDP-ME kinase (c), galactokinase (d), 
phosphomevalonate kinase (e) and mevalonate 5-diphosphate decarboxylase (f) are 
shown. The secondary structural elements are labeled in MVK. Regions where 
major structural deviation takes place (corresponding to the insertion part of the 
structure) are marked by arrows.  
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(Figure 14a, b, c, d, e, f).  In CDP-ME kinase, instead of two long helices, the region 
corresponding to MVK helices G and H is composed of two long β-strands as well as a 
short α-helix (Figure 14c). Galactokinase has an additional helix and a short loop 
insertion between two helices equivalent to helices F and G in MVK. In addition, 
compared with the helix F in MVK, its equivalent in the galactokinase is much longer 
(Figure 14d). HSK has a short strand in the location corresponding to the MVK helix F. 
It also has an additional helix insertion between the equivalents to MVK helices H and I 
(Figure 14b). Mevalonate 5- diphosphate decarboxylase has one more helix after the 
equivalent to the helix J in MVK. Furthermore, its structural element corresponding to 
the helix G in MVK is bent. (Figure 14f) 
The comparison between the rat and M. jannaschii enzymes 
           The structure of the rat MVK was solved shortly after the M. jannaschii MVK 
structure. Overall, the structures are similar (Figure 11b). Superimposition of two 
structures generates an r.m.s.d at about 1.47 Å. Several differences in the structural 
elements have been identified. First, the long loop connecting the strand d and the helix 
A has a different conformation and in the rat MVK, this loop is apparently longer. 
Second, the helices A and C are not superimposed well. These two regions are involved 
in the nucleoside base binding and Mg2+ coordination, respectively. As will be discussed 
in later sections, difference in these regions may affect the mode of ATP binding.    
           Furthermore, between helices B and C in the rat MVK, there is a flap in contact 
with a long C-terminal extension that folds into the N-domain and joins the large β-sheet. 
Both the flap and the long C-terminal extension are missing in the M. jannaschii MVK.  
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Figure 15 Superose 6 Size-exclusion Chromatography of MVK. 
 
a. The Elution Profile of MVK 
b. Calibration of the Superose-6 Column 
Thyroglobulin, bovine gamma-globulin, chicken ovalbumin, equine myoglobin and 
vitamin 12 (from left to right) were used to calibrate the size-exclusion column. The  
logarithm of the molecular weight (MW) and the elution volume were fit with linear  
regression. The resulting equation was used to estimate the molecular weight of  
MVK from its elution volume. 
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Figure 16 Oligomer State of MVK and HSK Crystal Structures. 
 
a. The Dimer of the Rat MVK 
 
b. The Dimer of the M. jannaschii HSK 
 
 
 
Interestingly, Val 377 is located in the long C-terminal extension and the human 
equivalent to this residue is related to HIDS. Therefore, this part of the structure might 
be involved in protein stability. The M. jannaschii protein, as a thermophilic protein, 
may have a different stability profile from that of the rat protein, which probably 
explains the difference in this region. Finally, in the C-terminal domain, the helix G and 
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the following loop show large structural deviation between the rat and M. jannaschii 
proteins, which, as will be discussed in the next section, may have implications in the 
dimerization of MVK.  
Oligomeric state of MVK 
           The size-exclusion chromatography studies using superose 6 column (analytical 
grade with separation range between 5 to 5000 KD) suggested that the molecular weight 
of MVK is 90646 Da (Figure 15). As the molecular weight for a monomer is 37340 Da 
(based on its amino acid sequence), it is estimated that MVK exists as a dimer in 
solution. In the crystal structure, the M. jannaschii MVK has only one molecule in the 
asymmetric unit. In order to reveal any possible dimers whose dimeric symmetry axis is 
coincident with the crystal symmetry, symmetry operation was applied and all molecules 
in a unit cell were inspected. However, no dimer was found.  
           Dimeric forms were reported from the crystal structures of both the rat MVK and 
the M. jannaschii HSK. In both proteins, the dimeric interface is at the C-domain. 
Interestingly, in the rat MVK, helices H, G and I are involved in the protein-protein 
interaction, which generates an elongated dimer (Figure 16a). In HSK, however, only the 
equivalent to the helix G is involved in the dimer formation. Consequently, the HSK 
dimer has a different shape and the dimeric interface from those of the rat MVK dimer 
(Figure 16b), which indicates that the dimer formation is not through a conserved 
mechanism within the GHMP kinase family. Sequence comparison also shows that the 
hydrophobic residues in the dimeric interface in the rat MVK are not conserved in the M. 
jannaschii protein. As stated earlier, the helix G also shows structural differences in the 
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rat and M. jannaschii MVK. Therefore, the dimeric interactions in the M. jannaschii 
MVK may be different and weaker than that from the rat enzyme, which makes it readily 
disrupted by crystal packing forces.  
Interaction between structural motifs 
           Cys 281 in the motif III is approximately 2.0 Å from Cys 107 in the motif II. The 
relative orientation of these two residues, as well as a continuous electron density 
connecting their side chains, suggest a disulfide bond (Figure 17). In MVKs from other 
sources, only the residue corresponding to Cys 281 is conserved. Neither of these two  
 
 
 
Figure 17 Interactions between Structural Motifs. 
 
Motif I (green), II (golden) and III (cyan) are shown in this figure. The disulfide 
bond between Cys 107 and Cys 281 are shown. The residues Glu 14, His 15 and Lys 
272 are also shown.   The residues are colored according to the atom types: carbon 
(white); oxygen (red); nitrogen (blue) and sulfur (yellow). This coloring scheme is 
applied to residues and ligands throughout unless described elsewhere.  
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cysteines is conserved among other GHMP kinases, except the bacteria 
phosphomevalonate kinase, in which the residue equivalent to Cys 281 is conserved. 
This residue probably plays some roles in binding the mevalonate moiety of the substrate. 
The disulfide bond might have its unique function in the M. jannaschii MVK, probably 
by “locking” the relative orientation of motif II and III and contributing to its 
thermostability.   
           Lys 272 in motif III is 3.1 Å away from Glu 14, a motif I residue (Figure 17). 
Their relative orientation indicates the formation of a salt bridge that is strictly conserved 
among MVKs. The mutation of His 20 in the rat enzyme (equivalent to His 15 in the M. 
jannaschii enzyme) to lysine completely abolished the activity of this protein, while its 
mutation to leucine or tyrosine only moderately decreased the enzyme activity (105). 
The destructive consequence of H20K is probably due to its disruptive effects on this 
salt bridge. This salt bridge also exists in phosphomevalonate kinase and galactose 
kinase (where the lysine is replaced with an arginine) crystal structures.  
The active site 
           The active site of MVK is located in a cleft between the N- and C-domains. The 
phosphate-binding loop, composed of a long loop and the N-terminus of the helix B, 
forms a “ridge” dividing the active site cavity into two pockets. The smaller pocket 
accommodates the purine and sugar moieties of ATP, while the larger pocket has a 
negatively charged patch around the residue Glu 144 that provides the site for Mg2+ ion 
coordination. There is also a positively charged region extended from the phosphate-
binding loop towards the residue His 15 in the larger pocket, probably as the binding site  
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Figure 18 Active Site Pocket of GHMP Kinases. 
 
Active site cavities of MVK (a), HSK (b), CDP-ME kinase (c), galactokinase (d), 
phosphomevalonate kinase (e) and mevalonate 5-diphosphate decarboxylase (f) are 
shown. The yellow loop is the phosphate-binding loop. The catalytic salt bridge as 
well as the ADP and dioxane ligands is displayed.  The surface is colored according 
to the electrostatic potential: negatively charged (red), uncharged (white) and 
positively charge (blue). This coloring scheme is applied to other surfaces in figures 
throughout this dissertation unless described elsewhere. 
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for mevalonate, since its positive charges are compatible with the carboxyl group as well 
as the 3’ and 5’-hydroxyl groups of mevalonate.   
           In the apoprotein crystal structure, a dioxane molecule is bound about 3.0 Å from 
the main chain amides of residues Ser 111 and Ser 112, probably forming hydrogen 
bonds. In the HSK crystal structure in complex with ADP, the β-phosphate group 
occupies this position and forms hydrogen bonds with main chain amides of Ser 97 and 
Ser 98 (equivalents to Ser 111 and Ser 112). Therefore, it is likely that the dioxane 
molecule occupies the phosphate position, which has been verified by the crystal 
structures in complex with nucleotide ligands, as will be described later in this chapter.  
           Conserved residues and the three structural motifs are aligned around the active 
site cavity. Residues from motif II form the phosphate-binding loop that is involved in 
ATP binding. Although distant in sequence, motif I and III are in proximity in the crystal 
structure. Together, they form the mevalonate binding site. Asp 155 forms a salt bridge 
with the residue Lys 8, with distance 2.72 Å. As will be presented later, this salt bridge, 
in particular the residue Asp 155, plays the central role for the enzyme catalysis.  
           The active site pockets of MVK, HSK, CDP-ME kinase, galactokinase, 
phosphomevalonate kinase and mevalonate 5-diphosphate decarboxylase are compared 
in Figure 18. One common feature is the phosphate-binding loop that has a similar 
conformation in all six proteins. The salt bridge formed by an aspartate and a lysine 
residues exists in MVK, CDP-ME kinase, phosphomevalonate kinase and galactokinase 
(where an arginine is in place of the lysine) crystal structures, suggesting a conserved 
catalytic mechanism based on a catalytic general base. HSK does not have the lysine 
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residue and has an asparagines residue in place of the aspartate. HSK is known to lack a 
catalytic base and use a transition state stabilization mechanism for catalysis, which is 
consistent with its loss of this salt bridge (106). Mevalonate 5-diphosphate 
decarboxylase does not have any residues equivalent to this pair and its active site 
pocket is relatively different from other GHMP kinases (Figure 18), which is consistent 
with the fact that the reaction it catalyzes is different from a simple phosphoryl transfer.   
The nucleotide usage of MVK 
           Enzyme activity assays showed, in addition to ATP, the M. jannaschii MVK can 
also use GTP, UTP and CTP as the phosphoryl donor. Our assay method based on the 
PK/LDH coupling system does not permit to compare the nucleotide specificity, because 
PK prefers ADP as its substrate much more than CDP, GDP and UDP. Therefore, the 
kinetic property of MVK was characterized by using ATP as the phosphoryl donor. The 
mean Km values for ATP and (RS)-mevalonate were determined to be 184.91±20.94 µM 
and 20.09±2.68 µM, respectively. This is comparable with the data from the human 
enzyme (Table 7). We also investigated the product inhibition to MVK. Because ADP is 
the substrate of the PK/LDH coupling system, the non-hydrolysable analog ADPβS was 
used to analyze the product inhibition by ADP and its Ki was determined to be 
90.96±11.90 µM. AMP did not inhibit MVK at 2 mM concentration, which suggests that 
a minimal di-phosphate moiety is necessary for nucleotide binding. GDPβS and 
pyrophosphate were not inhibitory at 2 mM, either, indicating that an adenine base is 
required for inhibition by the nucleotide. (Table 7) 
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Figure 19 The Electron Density of Nucleotide Ligands. 
 
Electron densities at 1σ in 2Fo-Fc maps for nucleotide ligands AMPPCP (a), ADP 
(b), ADPβS (c) and UTP (d) are shown in green. The phosphorus atoms are colored 
in purple and the rest atoms are colored as described earlier.  
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Determining the ligand bound crystal structures 
           Using the apoprotein structure as the model, the initial 2Fo-Fc and Fo-Fc maps 
showed an additional density that resembled a putative ligand. In general, phosphate 
groups had the best density. The density for nucleoside base was good in AMPPCP, 
ADP and ADPβS but weak in UTP. The sugar moiety had poor density in both 
AMPPCP and UTP, leading to the discontinuity in this region. The model phases were 
then improved using Shake ‘n’ wARP, which significantly improved the ligand electron 
density. As a result, AMPPCP was totally connected and the pyrimidine ring of UTP 
was clearly revealed. These results further validated the existence of the ligand in the 
crystal. The ligand was fit into the electron density and after several rounds of 
refinement, the group occupancy of AMPPCP, ADP, ADPβS and UTP were refined to 
0.72, 0.84, 0.83 and 0.80 respectively. The final 2Fo-Fc map for nucleotide ligands are 
shown in Figure 19. The final refinement statistics are summarized in table 3.  
           For GPP, FPP and GGPP bound MVK crystals, after initial refinement and map 
calculation in REFMAC, a density contoured at 5 σ resembling a pyrophosphate moiety 
was found near the phosphate-binding loop. Shake ‘n’ wARP and composite omit map 
produced some more densities extending from the pyrophosphate. However, the nature 
of that part of the density is unclear, since it could be either from the disordered carbon 
chain of terpenoids or a solvent associated with the pyrophosphate moiety. Therefore, 
only a pyrophosphate has been built.   
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Table 7 Kinetic Studies on MVK. 
 
NI: No inhibition 
*:    Taken from Reference 83 
**:  Taken from Reference 89 
Compound Constant M.jannachii MVK Human MVK 
Pyrophosphate  Ki            NI (to 2 mM)
Geranyl Pyrophosphate  Ki 208.41 µM 116 nM*
Farnesol Ki            NI (to 2 mM) 72 µM*
Farnesyl Pyrophosphate Ki 13.02 µM 104 nM*
Farnesyl Monophosphate Ki 6.54 µM
Farnesyl Triphosphate Ki 25.03 µM
Geranylgeraniol Ki NI (to 2 mM)  
Geranylgeranyl Pyrophosphate Ki 1.02 µM 59 nM*
Geranylgeranyl Monophosphate Ki 0.66 µM
Geranylgeranyl Triphosphate Ki 1.65 µM
ATP Km     184.91±20.94 µM 440 µM* or 74 µM**
(RS)-mevalonate Km 20.09±2.68 µM 150 µM* or 24 µM** 
ADPβS Ki 90.96±11.90 µM
GDPβS Ki NI (to 2 mM)  
AMP Ki NI (to 2 mM)  
 
 
 
MVK shows little flexibility under different liganded states  
           The crystal structures of MVK in complex with AMPPCP, ADP, ADPβS and 
UTP were compared and no major conformation differences were identified (Figure 20a). 
The only exception is the disulfide bond between residues Cys 107 and Cys 281. In the 
UTP bound structure, the distance between the two sulfur atoms is about 3.35 Å, 
indicating that the disulfide bond is broken. In all other structures, this distance is less 
than 2.20 Å, consistent with the existence of the disulfide bond. 
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           Positions of the phosphate-binding loop in MVK structures under different 
liganded states are nearly identical, despite the fact that this structural motif is mainly 
composed of small residues and might be relatively flexible. Interestingly, the main 
chain amides of Ser 106, Cys 107, Gly 108 and Leu109 form an extensive hydrogen 
bond network via an ordered water molecule (Figure 20b). This feature also exists in 
several other GHMP kinase crystal structures, including HSK, phosphomevalonate 
kinase, the rat MVK and CDP-ME kinase and may contribute to the rigid conformation 
of the phosphate-binding loop.  
The crystal structure of the MVK-AMPPCP-Mg2+ reveals the mode of ATP binding 
and Mg2+ coordination      
           Consistent with the published rat MVK-ATP-Mg2+ structure (96), AMPPCP is in 
an anti conformation in the MVK-AMPPCP-Mg2+ crystal structure. The phosphate 
groups are bound to the phosphate-binding loop via several hydrogen bonds with main 
chain amides. Interaction with the phosphate-binding loop is mainly made by the β- and 
γ-phosphate groups (Figure 21a). 
           The Mg2+ ion is octahedral coordinated, by three water molecules as well as the 
side chain of Ser 112 and oxygen atoms from the β- and γ-phosphate groups of 
AMPPCP (Figure 22a). The three water molecules and the β-phosphate oxygen form a 
plane with the Mg2+ ion in the center, while Ser 112 and the γ-phosphate oxygen 
coordinate from the above and below, respectively. Water molecules involved in Mg2+ 
coordination form hydrogen bonds with side chains of several conserved residues, 
including Ser 112, Asp 155 and Glu 144. Interestingly, the conserved residue Glu144  
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Figure 20 Overall Structures. 
 
a. The Alignment of MVK Crystal Structures in Complex With AMPPCP 
(green), ADP (cyan), ADPβS (golden) UTP (yellow), FPP(purple) and Dioxane 
(red) 
 
b. An Conserved Water Molecule Coordinated by the Phosphate-binding Loop
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Figure 21 The Binding Mode of the Phosphate Groups. 
 
a. The Interaction of the Phosphate Groups of AMPPCP with the Phosphate-binding Loop 
 
b. The Interaction of the Phosphate Groups of ADP with the Phosphate-binding Loop 
 
c. The Interaction of the Phosphate Groups of UTP with the Phosphate-binding Loop 
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does not directly coordinate the Mg2+ ion, as was reported in the rat MVK crystal 
structure (96). In the rat MVK, the distance between the equivalent glutamate residue 
(Glu 193) and the Mg2+ ion is closer (2.84 Å in the rat protein versus 3.95 Å in the M. 
jannaschii protein). After superimposing two MVK molecules, it is apparent that, the 
AMPPCP-Mg2+ in the M. jannaschii MVK is not aligned well with the ATP-Mg2+ in the 
rat MVK (Figure 22b). As mentioned previously, several structural differences are 
observed between the rat and M. jannaschii MVK, near the nucleoside base binding 
pocket, which probably affects the binding of the nucleotide ligand and Mg2+ 
coordination.  
           The two hydroxyl groups on the ribose moiety form hydrogen bonds with the 
carbonyl of Asp 72 and also form indirect hydrogen bonds (bridged by a water molecule) 
with the main chain amides of Lys 74, Tyr 75 and Cys 76. The purine ring is involved in 
both hydrophobic and hydrogen bonding interactions with MVK. The pocket that 
accommodates the nucleoside base is relatively hydrophobic and the adenosine ring is 
located in a site surrounded by residues Leu 46, Leu 48, Leu 51, Ile 99, Ile 105 and Ile 
115. Hydrogen bonding is formed between N6 of the adenosine ring and the side chain 
of Asp 50. In addition, the side chain and main chain amide of Ser 101 form indirect 
hydrogen bonds with N7 and N6 of the adenosine ring, respectively. Main chain amides 
of Asn 49 and Asp 50 also form indirect hydrogen bonds with the N1 of the purine ring 
(Figure 23a). The hydrogen bonding pattern may provide the basis for the selectivity on 
the nucleotide usage.     
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The potential site for the phosphoryl acceptor   
           Although mevalonate was included in the crystallization condition, no electron 
density could be identified as this ligand. Instead, a dioxane molecule was found to 
partially overlap with the potential mevalonate binding site, which may compete with 
mevalonate and preclude its binding.  
           In the MVK-AMPPCP-Mg2+ structure, the side chains of Asp 155 and Lys 8 form 
a hydrogen bond with an ordered water molecule. This same water molecule is also close 
to the γ-phosphorus of AMPPCP (3.46 Å) (Figure 24a). In addition, after superimposing 
the HSK-homoserine structure with the MVK-AMPPCP-Mg2+ structure, we aligned the 
4’-hydroxyl group of homoserine (its phosphoryl acceptor) to almost the same location 
of this water molecule. Furthermore, this water molecule, the γ-phosphorus and the 
bridging carbon atom between the β- and γ-phosphorus of AMPPCP are approximately 
in the “in-line” geometry. All these clues suggest that the location of this ordered water 
molecule marks the binding site for the phosphoryl acceptor, the 5’-hydroxyl group of 
mevalonate. Based on the position of this ordered water molecule and the HSK-
homoserine structure superimposed to MVK, we modeled a mevalonate molecule into 
the MVK active site (Figure 24b). As expected, the mevalonate was modeled to the 
positively charged area in this pocket. Its carboxyl group is facing the side chain of Ala 
276, whose equivalent residue in the human enzyme (Ala 334) is indicated in HIDS. 
Probably, the introduction of a bulkier side chain of the threonine in the A334T mutant 
from the HIDS patients interferes with the carboxyl group and decreases the binding of 
mevalonate.  
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Figure 22 The Mode of Mg2+ Coordination and the Comparison of the Rat and M. 
jannaschii Enzymes. 
 
a. The Mode of Mg2+ Coordination 
The electron density (contoured at 1σ) around the Mg2+ ion (cyan) is shown in 
green. The residues important for Mg2+ coordination are displayed. The 
coordination water molecules are shown as red spheres. The hydrogen bonds are 
displayed in black dashed line.  
 
b. The Structural Alignment of the Rat and M. jannaschii MVK   
The M. jannaschii (blue) and rat (yellow) MVKs are superimposed. The Mg2+, Glu 
144 and AMPPCP from M .jannaschii protein is shown in cyan, while the Mg2+, Glu 
193 and ATP from rat protein is shown in golden. 
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           Is this ordered water molecule an actual phosphoryl acceptor? Though it was 
reported that HSK has an ATPase activity in addition to its kinase activity (107), we did 
not find the ATPase activity from MVK based on our enzyme activity assay. Co-
crystallization of MVK with ATP showed only an ADP density in the active site, which  
might suggest that in the special situation within a crystal, where the protein 
concentration is very high, MVK could hydrolyze ATP, as has been demonstrated in 
other ATP binding proteins (101). However, no direct evidence exists for this hypothesis.  
 
 
 
 
 
Figure 23 The Binding Mode of the Nucleoside Base. 
 
a. The Binding Mode of the Nucleoside base of AMPPCP 
 
b. The Binding Mode of the Nucleoside base of ADP 
 
c.  The Binding Mode of the Nucleoside base of UTP 
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Figure 24 The Phosphoryl Acceptor Binding Site. 
 
a. The Potential Phosphoryl Acceptor Site  
The ordered water molecule is shown as a red sphere. AMPPCP and catalytic 
residues Asp 155 and Lys 8 are displayed. The hydrogen bonds are displayed as 
green dashed line and the bonding distances are displayed in Å. 
 
b. The Modeling of a Mevalonate Molecule 
The phosphate-binding loop is shown in green. Homoserine from the superimposed 
HSK is in cyan and the modeled mevalonate is colored according to the atom types. 
AMPPCP as well as key residues Lys 8, Asp 155 and Ala 276 are displayed and 
colored according to the atom types. The phosphorus of AMPPCP are colored in 
purple.  
 
The crystal structure of the MVK-ADP-Mg2+ and the basis for product inhibition 
by ADP 
           The binding mode of ADP was revealed in the crystal structures of the MVK-
ADP-Mg2+ and MVK-ADPβS-Mg2+, solved to 2.4 Å and 2.3 Å, respectively. In both 
structures, the ligands have almost exactly the same conformation. Therefore, we will 
focus discussion on the MVK-ADP-Mg2+ structure. In ADP, both the α- and β-phosphate 
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groups are in close contact with the phosphate-binding loop and participate in Mg2+ 
coordination (Figure 21b). As was also revealed in the MVK-AMPPCP-Mg2+ structure, 
a di-phosphate moiety is involved in making hydrogen bond with the phosphate-binding 
loop. This will again be demonstrated in the UTP and FPP (as from its partial density) 
bound structures in later sections. AMP certainly does not have this di-phosphate moiety, 
which probably prevents it from making optimal binding to MVK, explaining its lack of 
inhibition.  
           After superimposing the MVK crystal structure in complex with AMPPCP and 
ADP, we found that there is a nearly 60º of rotation in the α-phosphate group, by which 
the α-phosphate group in ADP is brought into contact with the phosphate-binding loop 
and replaces one water molecule at the Mg2+ coordination position. As suggested from 
the crystal structures of HSK (101, 106) and the rat MVK (96), the phosphate groups of 
the nucleotide are flexible. In the rat MVK (96), the ATP phosphate tail can be fit with 
two conformations. The major conformation is similar to the AMPPCP structure 
reported in this dissertation, with the β- and γ-phosphate involved in Mg2+ coordination. 
In the minor conformation, the α-phosphate group also coordinates Mg2+, which is 
similar to the ADP structure (minus the γ-phosphate). The flexibility of the phosphate 
groups ensures the phosphate groups of ADP to make sufficient interactions with the 
phosphate-binding loop and forms a stable complex with MVK, which might cause the 
product inhibition. 
           Compared with AMPPCP, the ribose moiety in ADP is twisted for about 45º and, 
with the purine ring as a rigid body, has a shift for about 1.3 Å. As in AMPPCP, the 
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purine ring nitrogen atoms N6 and N7 form the same hydrogen bonding interactions 
with the protein. However, due to the shift of the purine ring, N1 does not form 
hydrogen bonding interactions with the protein. Instead, N3 of the adenosine ring forms 
a direct hydrogen bond with the carbonyl of Asp 72 and indirect hydrogen bond with 
main chain amides of Tyr 75 and Cys 76 (Figure 23b). 
The binding mode of an alternative phosphoryl donor 
           In order to reveal the binding mode of alternative nucleotide ligands, we soaked 
or co-crystallized GTP, UTP and CTP with MVK. Only UTP showed an unambiguous 
density, in which the α- and β-phosphate groups are associated with the phosphate-
binding loop and form several hydrogen bonds (Figure 21c). Interestingly, the γ-
phosphate group of UTP is rotated approximately 180º away from the phosphate-binding 
loop and does not form hydrogen bonding interactions with its residues. Instead, it forms 
hydrogen bonds with the side chains of Ser 200 and Arg 196.  
           The Mg2+ is located at approximately the same place as that in the MVK-
AMPPCP-Mg2+ and MVK-ADP-Mg2+ structures, coordinated by the side chain of Ser 
112, three water molecules and one α-phosphate oxygen. From the mechanistic point of 
view, the γ-phosphate oxygen atom should be involved in Mg2+ coordination in order for 
the nucleotide to be activated for the phosphoryl transfer. In the UTP bound structure 
presented here, the γ-phosphoate group is not involved in Mg2+ coordination and it is 
relatively far away from the catalytic Asp 155-Lys 8 pair. Therefore, it is not likely to be 
in the proper in-line geometry required for the enzyme activity and our structure may 
represent a non-productive binding mode that is energetically most stable. It is certainly 
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possible that conformational changes after mevalonate binding might lead to a proper 
UTP conformation, considering the flexibility of the phosphate groups. 
           There is no interaction between the ribose moiety and the protein, which is 
consistent with the weaker electron density in this region (Figure 19d). Since UTP has a 
pyrimidine ring that has different hydrogen bonding and geometry properties from the 
purine ring of AMPPCP, it is not surprising to find that the nucleoside base of UTP 
adopts a different binding mode. In the crystal structure, the pyrimidine ring of UTP is 
bound to a site close to the aromatic ring of Tyr 75 and the side chain of Ile 115, 
approximately the ribose moiety binding site of AMPPCP and ADP. N3 of the uridine 
moiety forms one hydrogen bond with the main chain carbonyl of residue Asp 72. Both 
N3 and the carbonyl oxygen O4 of the uridine ring also form indirect hydrogen bonding 
interactions with main chain amides of Lys 74 and Tyr 75 via a bridging water molecule 
(Figure 23c). Interestingly, most of these hydrogen bonding sites are used by the purine 
atom N3 in ADP.   
           Compared with the adenosine moiety in AMPPCP and ADP, fewer hydrogen 
bonds are formed between the uridine moiety and MVK. Normally, both uridine 
carbonyl oxgens O2 and O4, as well as N3, make hydrogen bonding interactions with 
protein residues, as was demonstrated in the dUTPase crystal structures (108). Therefore, 
the binding of UTP in MVK is not optimized. The hydrogen bonding pattern between 
the nucleoside base and the protein suggests the nucleoside base binding pocket is 
probably selective for the adenine ring, as adenine forms more hydrogen bonds with the 
protein. However, even for adenine, its binding modes are slightly different in the 
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AMPPCP and ADP bound crystal structures. The uridine, on the other hand, binds quite 
differently. These data suggest that the nucleoside base binding pocket has a degenerate 
nature, probably based on its relatively large size and the abundance of potential 
hydrogen bonding partners which allows the base ring to be fit in different orientations. 
This probably explains why alternative nucleotides can be used as phosphoryl donors.  
The possible mechanism for MVK 
           Based on the available data, a probable mechanism for MVK is proposed (Figure 
25). First, the substrate binding is mediated by the three conserved motifs. Motif I and 
III are involved in mevalonate binding. Motif II provides the interactions sites for a di-
phosphate group and is critical for the nucleotide binding. The nucleoside base binding 
pocket accommodates the adenine ring of ATP. 
           Second, the catalysis is performed by the conserved aspartate residue (Asp 155) 
that functions as a general base by abstracting a proton from the nucleophilic 5’-
hydroxyl group of mevalonate. A nearby lysine residue (Lys 8) lowers the pKa of that 
hydroxyl group and may also neutralize the negative charges accumulated on the γ-
phosphorus during the transition state. The transition state is further stabilized by the 
positively charged N-terminus of the helix B pointing towards the β- and γ-phosphate 
groups. The reaction is promoted by an Mg2+ ion coordinated by Ser 112 and Glu 144 
(via bridging water molecules) (Figure 25). 
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Figure 25 The Proposed Mechanism for the M. jannaschii MVK. 
 
 
Analysis of inhibition by terpenoids and their analogs 
           We then investigated the effect on the terpenoid inhibition by the carbon chain 
and phosphate groups. We found that the length of the carbon chain is a positive 
determinant for inhibition, with Ki of GGPP < FPP < GPP, which is consistent with 
studies in human enzymes (Table 7) (83). The effect of the phosphate groups is less clear. 
Interestingly, the monophosphate group was sufficient for inhibition, which is different 
from the nucleotide as mentioned in section 2. 10. Farnesol and geranylgeraniol, 
however, did not show any inhibitory effects at a concentration of 2 mM. Therefore, at 
least one phosphate group is required for the terpenoid inhibition (Table 7).  
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           Why is the di-phosphate moiety of terpenoids not required for inhibition? It is 
probable that as hydrophilic ligands, nucleotides bind to MVK via electrostatic 
interactions, which is mainly through the interaction with the phosphate-binding loop. 
As a monophophate group is not sufficient to maintain this interaction, AMP cannot 
inhibit MVK. As hydrophobic ligands, terpenoids might largely rely on the contribution 
by its carbon chain to bind the protein, as the effect of the carbon chain length has 
already demonstrated. Although the interaction with the phosphate-binding loop is still 
necessary, its contribution to the overall binding is not as prominent as in nucleotides. 
Therefore, the weakening of the interaction with the phosphate-binding loop by losing 
one phosphate group might be readily compensated by the hydrophobic interactions.  
           The Ki values for GPP, FPP and GGPP of the M. jannaschii enzyme are much 
higher that those of the human enzyme (Table 7). However, the Ki for FPP in our 
enzyme is similar to that of the S. aureus MVK (~45 µM) (79). As the phylogenetic 
analysis suggested that the archaeal MVK is more closely related to the prokaryotic 
enzyme (52), our observation probably revealed the difference in the response to the 
terpenoid feed-back inhibition by the eukaryotic and prokaryotic/archaea enzymes. In 
section 2.6, we compared the crystal structure of the M. jannaschii MVK with rat MVK. 
Differences in the ATP site were identified, which might be the underlining cause for the 
difference in the terpenoid sensitivity.  
Possible mode for terpenoid inhibition 
          Crystallization trials with terpenoids (GPP, FPP and GGPP) and MVK reveal only 
a pyrophosphate moiety that occupies the same location of the β-and γ-phosphate groups            
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Figure 26  The Terpenoids Binding Site. 
The pyrophosphate moiety (purple: phosphorus; red: oxygen) of a FPP molecule is 
in complex with MVK. The grey molecule is an AMPPCP superimposed onto this 
structure. 
 
of AMPPCP. This is consistent with the competitive nature of terpenoid inhibitors with 
ATP (81, 83) (Figure 26). Earlier results also show that terpenoids are uncompetitive 
with mevalonate (81, 83), which may indicate that the binding of mevalonate is required 
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for the proper binding of terpenoids. As mevalonate does not bind in our crystal 
structures, this probably explains why the carbon chain is disordered in these structures.  
           But where could the carbon chain go? Docking experiment suggest that the 
carbon chain can be placed into the nucleoside base binding pocket. This pocket is 
relatively hydrophobic and may readily accommodate the hydrophobic carbon chain. We 
certainly cannot rule out other possibilities, as no experimental evidence is available. 
The other question is about the mechanism on how mevalonate affects the terpenoid 
binding? In HSK, the binding of the substrate homoserine leads to the closure of the 
active site pocket (106). Maybe a similar event is triggered by the presence of 
mevalonate in MVK, which could form a more hydrophobic binding environment that is 
preferred by the carbon chain of terpenoids.   
Overview of virtual screening  
           To further explore the active site of MVK, virtual screening was performed. More 
than 40,000 NCI compounds and 10,000 Maybridge compounds were docked into the 
MVK active site with FLEXX. In addition, about 78,000 compounds from the 
LUDI/ACD library were docked using the program LUDI (Table 8). After visual 
inspection, 29 compounds were tested, and the results suggested that two compounds 
showed weak inhibition of MVK. (Table 9) These two compounds were further 
characterized, which included structure activity relationship study based on one of the 
compounds. Further virtual screening was performed using the “anchoring” moieties 
identified from the two hits; however, there was no significant improvement in the 
inhibitory effect.  
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Table 8 Virtual Screening Statistics. 
Number of 
Molecules NCI Maybridge LUDI/ACD 
Initial 40,000 12,000 78,000 
Extracted (Cscore, 
FLEXX) 400 120
              
       N/A 
Visual Inspection 400 120 300 
Ordered for Testing 9 9 11 
Inhibiting MVK 1 1 0 
Inhibiting PK/LDH 
system 2 5 1 
                             
Visual inspection 
           Visual inspection suggested that the top docking hits tend to cluster around the 
phosphate-binding loop. A majority of the compounds have an aromatic ring structure as 
the “anchoring” group which was docked near the phosphate-binding loop. Hydrogen 
bonding with main chain amides was predicted (Figure 27a, b), which partially mimics 
the binding of phosphate groups to this structural motif. The other part of the compounds 
extends away from the phosphate-binding loop, mostly into the potential mevalonate 
binding site. The apparent central role of the phosphate-binding loop for docking is 
probably due to its main chain amides that provide most of the interaction sites and 
ensure that the electrostatic interactions play a large role in the total binding energy. 
However, this pattern can potentially create two problems: i) the docking and scoring 
may be less accurate because docking programs are insufficient to estimate electrostatic 
interactions (42) and ii) the compounds may show nonspecific inhibition since they have 
the same binding pattern as the phosphate (see below). In addition, the phosphate-
binding loop may cause low inhibition because of the compounds’ inability to compete 
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Table 9 FLEXX Hits Chosen for Initial Validation. 
Compound  Structure F score CScore MW (Da) LogP
SPB00929 
 
-38.74 5 378.28 1.72
RH01369 
 
-39.07 5 325.28 2.26
HTS04725 
 
-38.35 4 377.28 2.45
ML00294 
 
-38.24 5 384.35 2.96
HTS08391 
 
-36.42 4 404.30 3.31
SPB01501 
 
-39.44 3 324.34 3.33
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  Table 9 Continued.  
 
Compound  Structure F score CScore MW (Da) LogP
HTS08322 
 
-38.75 4 395.40 2.57
HTS03748 
 
-40.98 4 315.28 0.98
HTS07725 
 
-43.99 5 327.09 0.69
NSC28620 
 
-39.40 4 311.23 0.98
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Table 9 Continued. 
Compound  Structure F score CScore MW (Da) LogP
NSC82020 -34.20
  
N/A 464.80 
 
N/A
NSC740 -40.80
  
N/A 454.44 -0.98
NSC1060 -38.10
  
N/A 604.60 2.83
NSC21356 -39.80
  
N/A 384.40 0.37
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Table 9 Continued.  
 
Compound  Structure F score CScore MW (Da) LogP
NSC21357 -41.20
  
N/A 676.40 0.29
NSC20799 -36.20
  
N/A 345.80 -4.27
NSC6883 -34.60
  
N/A 428.00 2.66
NSC12049 -38.30
  
N/A 486.60 2.65
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Figure 27 Two Virtual Screening Hits.   
 
a. The Predicted Binding Mode of HTS 08391 
 
b. The Predicted Binding Mode of NSC 28620 
 
c. The Partial Density for NSC28620 (contoured in pink at 1σ)  
 
d. The Binding Mode of the Pthalic Acid Determined from the Crystal Structure  
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with the phosphate groups from ATP that are optimized for binding to this loop through 
years of evolution. 
           To overcome this problem, we inspected more hits from the docking results and 
identified some that only interact with the nucleoside base binding pocket. Most of these 
compounds have been predicted to form hydrogen bonds with the side chains of Asp 50 
and Asp 72, as well as main chain amides or carbonyls from residues Ile 99, Ser 101, 
Asn 49 to Asp 50, Asp 72 and Lys 74 to Cys 76, which are similar to the interactions 
made by the purine or pyrimidine rings from the nucleotide ligands. However, these 
compounds have poor docking scores (Table 10), predicting that they are not good 
ligands.  
Initial inhibitor validation 
           In all, 10 Maybridge compounds and 10 NCI compounds from FLEXX docking 
and 11 ACD compounds from LUDI docking were selected for validation (Table 8, 9). 
Selected compounds were evaluated, and those with more than 10% inhibition at 10 µM 
concentration were subjected for further tests. Many compounds (ML00294, RH01369, 
SPB00929, HTS08322, HTS08391, NSC82020, NSC740 and 1-hydroxy-2-naphthoic 
acid) showed 10 to 30% inhibition against coupling enzymes (PK or LDH). This is 
probably due to the fact that most hits were selected for their affinity to the phosphate-
binding loop by FLEXX and might mimic the properties of the phosphate. As both PK 
and LDH have a ligand that contains phosphate moieties (ADP and NADH, respectively), 
these compounds might also bind and inhibit them. As mentioned before, compounds 
that only bind to the nucleoside base binding pocket were visualized, and they are  
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Table 10 Virtual Screening Hits Exploring the Nucleoside Base Binding Pocket. 
Compound  Structure F score CScore 
MW 
(Da) LogP
JFD03224 -27.05 5 274.24 2.28
CD07440 -24.85 5 247.26 1.62
HTS12557 -25.92 5 332.32 3.05
SPB06772 -27.88 5 362.40 2.38
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Table 10 Continued.  
Compound  Structure F score CScore 
MW 
(Da) LogP
       
HTS10933 
 
-24.40 5 299.76 3.20
  
XBX00106 -26.52 5 268.25 3.05
  
CD01617 -28.47 5 264.28 1.13
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associated with poor docking scores. Therefore, not surprisingly, in vitro tests on some 
of these compounds did not identify any inhibitory effects.   
           Two compounds NSC28620 (4-(2-carboxybenzoyl)phthalic acid) and HTS08391 
(3-[({6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl}amino)carbonyl]-2-pyrazinecarboxylic 
acid) were identified from initial assays. They showed weak inhibition (about 15%) at 10 
µM and did not inhibit the coupling enzymes at this concentration. Visual inspection 
showed these two compounds were predicted to be anchored to the phosphate-binding 
loop, via a phthalic acid (NSC28620) and pyrazinecarboxylic acid (HTS08391) moiety 
(Figure 27a, b). 
Determine IC50 and mode of inhibition  
           Because of its limited solubility and its inhibition on the PK/LDH system when 
the concentration is higher than 100 µM, compound HTS08391 could not be further 
tested to determine its IC50. However, compound NSC28620 could be characterized, and 
its IC50 was determined to be 255.9 µM. To determine the mode of its inhibition, 
reactions under 20 µM to 3 mM ATP and 0, 50 and 200 µM inhibitor were performed. 
The initial velocity was plotted with the ATP concentration, and the Lineweaver-Burke 
plot analysis indicated that compound NSC28620 competes with ATP. Therefore, its Ki 
value was directly estimated from the IC50 as 69.2 µM.  
Crystallographic studies  
           Compound NSC28620 was then co-crystallized with MVK and a complete 
dataset was collected from this crystal. No intact drug density could be identified after 
the electron density map was calculated, even if 2 mM of compound was included  
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Table 11 Structural Activity Studies Based on HTS08391. 
 
R2 "
R1"
N
N
O
O O
O
R3
R4
R5
R6  
Compound   R1 R2 R3 R4 R5 R6 F score Inhibition (10µM) 
HTS08391 N N H H H CF3 -36.42 14% 
HTS11134 N N Cl Cl H H -27.28 No inhibition 
HTS08512 C C  H H C(CH3)3 H -36.38 No inhibition 
HTS08390 C C H H H CF3 -36.11 No inhibition 
HTS03728 N N H H C(CH3)3 H -39.55 14% 
 
 
during the crystallization. However, a density near the phosphate-binding loop was 
identified and was verified by running the program Shake ‘n’ wARP. It was fit with a 
phthalic acid moiety (Figure 27c). Prediction from the docking study suggested that the 
carboxyl groups of the phthalic moiety make hydrogen bonds with main chains amides 
of Pro 104, Cys 107, Gly 108 and Ser 111 (Figure 27b). The same amides also form 
hydrogen bonds with the carboxyl groups of the phthalic acid moiety in the crystal 
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structure (Figure 27d). Interestingly, the orientation of the phthalic acid moiety in the 
crystal is different from the prediction, with the ring almost completely “flipped” 90º. 
Since we do not have the complete density, the exact binding mode of this compound 
remains unclear.                              
Structural activity studies   
           Structural activity studies were performed based on compound HTS08391 (Table 
11), because derivatives of this compound were commercially available. The only analog 
that still retained the inhibition is HTS03728 (about 14% at 10 µM). It has modifications 
on the distal benzene ring by removing the CF3 group (position R6) and adding a bulkier 
bultyl group at the neighboring position (position R5). As predicted, these positions are 
facing away from the active site pocket. Therefore, the functional groups on these 
positions may not contribute much to the binding energy. In comparison, compound 
HTS11134 has two chlorine atoms on the distal benzene ring at positions predicted to 
make more intimate interactions with the protein (position R3 and R4), which may 
introduce steric clashing. Two analogs, HTS08390 and HTS08512, have modifications 
on the pyrazinecarboxylic acid moiety by replacing the nitrogen with carbon (position 
R1 and R2), which converts this moiety to benzoic acid. Neither of these compounds 
showed inhibition. As HTS08391 and HTS03728 did show inhibition, it seems that the 
modification of the pyrazinecarboxylic acid moiety is the cause for inactivity, which 
stresses the importance of this moiety.  
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Table 12 Additional Virtual Screening Results. 
Compound  Structure F score CScore
MW 
(Da) LogP 
ST 201911 -39.70 5 322.09 0.56 
HTS07012 
 
-35.80 4 324.37 0.39 
HTS03680 
 
-35.94 4 327.11 0.65 
  524716 
 
-39.52 4 179.13 -0.53 
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Additional screening based on “anchoring” moieties 
           As discussed earlier, phthalic acid and pyrazinecarboxylic acid moieties were 
predicted to interact with the phosphate-binding loop and probably function as “anchors” 
for inhibitor binding. Based on this, we predicted that more inhibitors would be found by 
testing compounds that also contain these moieties. We searched the databases on the 
ZINC website (http://blaster.docking.org/zinc/), and all compounds that contain one of 
these two moieties were collected and docked using FLEXX. However, only four 
compounds showed good statistics. Visual inspection of the docking results suggested, 
like the compounds from initial screening, that these compounds were also predicted to 
be anchored to the phosphate-binding loop. Except for compound HTS07012, all were 
docked in such a way that the phthalic acid or pyrazinecarboxylic acid moiety interact 
with the phosphate-binding loop. Three of these compounds (HTS07012, HTS03680 and 
524716) were then purchased and tested. Only compound HTS03680 showed about 20% 
inhibition at 10 µM concentration. (Table 12)    
Conclusion 
           In this study, we solved the first MVK structure from M. jannaschii using 
selenium MAD phasing technique. Fold analysis shows that MVK shares a core 
structure with other GHMP kinases. The differences are mostly located in periphery 
regions. Therefore, the evolutionary conservation of this structural family is apparent, 
though the overall sequence identity among members are low. Comparison also shows a 
similar organization of the active pocket within most members of the GHMP family. An 
aspartate and lysine (arginine) pair is indicated as the catalytic residues in four out of six 
  
114
GHMP proteins compared, which suggests a conserved mechanism for the phosphoryl 
transfer.   
           To reveal the mechanism for substrate binding, catalysis and inhibition of MVK, 
we solved several ligand bound structures. Based on these crystallographic data, in 
combination with kinetic assay, the following conclusion were made: i) The phosphate-
binding loop is critical for the binding of nucleotides, terpenoids or compounds 
generated from virtual screening to the MVK active site. Although the loop itself does 
not change conformation, the phosphate tails of the nucleotides are flexible, which may 
ensure the minimization of the binding energy. A di-phosphate moiety is the minimal 
unit for interacting with the phosphate-binding loop. ii) The nucleoside base binding 
pocket provides several hydrogen bonding interaction sites. ATP seems to be preferred 
as its adenine ring forms the maximal amount of hydrogen bonding interactions allowed 
by the pocket. This pocket also has some degree of degeneracy, as is demonstrated in the 
UTP bound structure, in which a different binding orientation is adopted by the uridine 
ring. iii) The water in the structure near the catalytic residue Asp 155 indicates the 
potential location of the phosphoryl acceptor. Based on this, a mechanism consistent 
with all available data was proposed for MVK catalysis. iv) Studies on terpenoids 
explain why they are competitive with ATP. Different from nucleotides, the hydrophobic 
effect contributed by the carbon chains seems to play important roles for their binding. 
As the carbon chain is disordered in our structure where mevalonate does not bind, it is 
possible that the binding of mevalonate somehow facilitates the ordering of the carbon 
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chain, probably via MVK conformational changes, as a plausible mechanism for the 
uncompetitive nature of terpenoids with mevalonate.   
           Finally, we performed virtual screening in order to identify inhibitors against 
MVK. Most compounds with top scores were docked near the phosphate-binding loop. 
In vitro validation was then performed. Although some compounds showed limited 
inhibition, this process cannot be regarded with much success, since the inhibitory 
effects were weak and could not be improved through optimization. Therefore, the issue 
regarding the high false positive rate, as well as the potential problems associated with 
targeting the phosphate-binding loop, should be taken care of before a more successful 
experiment can be completed.  
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CHAPTER IV 
BACKGROUND OF CELL DIVISION AND FTSZ 
 
Bacterial Cell Division 
           Cell division is the fundamental process in any living systems. It is accomplished 
by two stages: partitioning of the genomic DNA and cytokinesis.        
           The bacterial genome is partitioned during DNA replication, as the replisome in 
the mid-cell provides the force for “pushing” DNA towards cell poles (109). Though the 
origin of the genomic DNA is segregated relatively early, the terminus remains at the 
mid-cell until the DNA dimer is resolved by enzymes such as XerCD and topoisomerase 
IV (109, 110, 111, 112). The partitioning of the bacteria genome is also facilitated by 
DNA condensation, mediated by proteins such as SMC (109, 113). As has been revealed 
by EM, the homodimer of a SMC has a symmetric structure composed of two long arms 
linked by a flexible hinge region (114). Individual arms contain the DNA binding site 
and the movement in the hinge region can shorten the distance between the arms, which 
may serve as the mechanism for DNA condensation (115).   
           The cytokinesis is initiated by the formation of the Z-ring, an apparatus mainly 
composed of the bacterial tubulin homolog FtsZ. The Z-ring formation is regulated by 
two mechanisms. The first is the nucleoid occlusion, as FtsZ cannot be assembled to 
form the Z-ring in the vicinity of the nucleoid. As the mid-cell region is normally 
occupied by the genomic DNA, this mechanism prevents the premature cytokinesis 
when the genome segregation has not yet completed. Recently, two proteins, Noc in B. 
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subtilis and SlmA in E. coli, have been identified as essential players for this process 
(116, 117). The second regulation mechanism is the Min system. (118, 119) It is 
composed of three proteins: MinC, MinD and MinE. MinC is the inhibitor of FtsZ 
polymerization and may also decrease the stability of the preformed Z-ring (118). MinC 
forms a functional complex with MinD and is anchored to the membrane by MinD. 
MinE is an anti-MinCD protein that displaces MinCD from the membrane. Importantly, 
MinCD complex oscillates from the pole to pole in E. coli every 30 to 60s, while MinE 
oscillates between the two ¾ positions, which creates a gradient of membrane-bound 
MinCD with its concentration at the cell poles to be the highest and at the mid-cell the 
lowest. This allows the Z-ring only to be assembled in the mid-cell area, if this region is 
cleared of the genomic DNA.  
           The exact mechanism of cytokinesis is still unclear, though it has been shown that 
FtsZ and the Z-ring are indispensable for this process (118). The Z-ring also functions as 
a platform for many other cell division proteins to bind. Some of them, like ZipA, may 
stabilize the ring structure and attach it to the membrane (118). Others, like FtsW, FtsN 
and FtsI, are involved in cell wall biosynthesis (118, 120). Their roles will be discussed 
in more details later.  
FtsZ 
FtsZ as a tubulin homolog                      
           FtsZ is the bacterial homolog of tubulin (Figure 28). Although the overall 
sequence similarity is low, FtsZ and tubulin have the similar structure (121). Both 
proteins have a GTPase activity and contain a tubulin signature motif GGGTG[S/T]G. 
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Like tubulin, FtsZ can self-assemble into long filaments promoted by the binding of 
GTP. Additionally, GTP analog GMPCPP also facilitates FtsZ assembly (122). 
GMPPNP and GTPγS, however, do not support polymerization, though the latter can 
stabilize the preformed FtsZ filaments (122, 123). Furthermore, GDP has been shown to 
destabilize preformed FtsZ filaments (123).  
           The morphology of FtsZ filaments have been investigated extensively with EM. 
Filaments assembled with GTP are mostly straight (122, 124). They can be either paired 
double protofilaments or sheets composed of multiple protofilaments. Divalent cations, 
like Ca2+, and polycations, such as DEAE-dextran, stabilize the FtsZ filaments and 
induce extensive bundling (125). This effect has also been observed when FtsZ binding 
proteins, such as ZipA, are incubated with FtsZ during the polymerization (126). FtsZ 
can also form helical tubes after being incubated with GDP in the presence of DEAE-
dextran (127), GTP in the presence of Ca2+ or GMPCPP in the presence of Mg2+ (128). It 
is important to note, however, that these helical tubes are formed by helical 
protofilament, which is different from microtubules that are formed by the association of 
13 to 14 straight tubulin protofilaments (129).  
           The crystal structures of FtsZ from M. jannaschii (121) M. tuberculosis (130), T. 
maritima (131) and P. aeruginosa (132) have been reported since 1998 (Table 13). Its 
N-domain is composed of a six-strand parallel β-sheet sandwiched by two and three 
helices on both sides, adopting the typical Rossmann-fold topology, containing the GTP 
binding site (121). Its C-domain is composed of a four-strand β-sheet packed with two 
helices (121). N- and C-domains are connected by a long central helix (121). There are  
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Table 13 List of FtsZ (a) and Tubulin (b) Crystal Structures. 
Unless mentioned, X-ray crystallography was used for structure determination. α-
and β-tubulins were used in these studies, unless mentioned otherwise.  
a 
Species Resolution (Å) PDB ID  Comments 
M. jannaschii 2.8 1FSZ monomer with GDP 
M. jannaschii 2.7 1W59 straight dimer with apoprotein 
M. jannaschii 2.4 1W5A straight dimer with Mg2+-GTP 
M. jannaschii 2.2 1W5B straight dimer with GTP 
M. jannaschii 2.5 1W58 monomer with GDP 
M. jannaschii 3.0 1W5E W319Y mutant in P1 space group 
 
T. maritima  2.0 1W5F domain swapped dimer, T7 mutated 
P. aeruginosa 2.1 1OFU complexed with inhibitor SulA 
M. tuberculosis 2.1 1RLU novel dimer with GTPγS 
M. tuberculosis 2.6 1RQ7 novle dimer with GDP 
M. tuberculosis 1.9 1RQ2 novel dimer with citrate 
 
b 
Species Resolution (Ǻ) PDB ID  Comments 
H. sapiens  3.0 1Z5W γ-tubulin 
S. scrofa   3.7 1TUB straight dimer with taxol (electron diffraction) 
B. taurus 3.5 1JFF straight dimer with taxol (electron diffraction) 
B. taurus 3.0 1TVK straight dimer with epothilone (electron diffraction) 
B. taurus 4.1 1Z2B with colchicine, vinblastine and a stathmin-like domain 
B. taurus 3.6 1SA0 with colchicine and a stathmin-like domain 
B. taurus 4.0 1FFX with GDP and a stathmin-like domain 
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several “tublin” loops, designated as T1 to T7. The T1 to T6 loops are around the 
nucleotide binding pocket of the N-domain and are involved in the binding of GTP. As 
shown in the M. tuberculosis FtsZ, some of these loops are flexible and can adopt 
different conformations depending on the nucleotide ligand. For example, when the γ-
phosphate is not present (apo or GDP state), the T3 loop is disordered (130).   
            
 
 
Figure 28 The Structural Alignment of Tubulin and FtsZ. 
  
The Rat Tubulin (golden) and M. tuberculosis FtsZ (Cyan) are superimposed and 
presented in the stereoscopic form.  
 
           The T7 loop is located in the C-domain and interacts with the nucleotide binding 
pocket of the neighboring FtsZ monomer in the FtsZ filament. Experimental data 
suggests that the GTPase activity is triggered by the polymerization of FtsZ. Mutations 
  
121
on the T7 loop severely decrease GTP hydrolysis, even in the mixture of mutant and 
wildtype proteins (133). These data are consistent with the hypothesis that the active site 
for GTPase is formed by two monomers, as has been suggested from studies on the 
tubulin. 
           A crystal structure of the M. jannaschii FtsZ protofilament has been reported 
(131). It shows that two key residues from the T7 loop (Asp 235 and Asp 238) insert into 
the nucleotide binding pocket in the neighboring monomer, which polarizes a water 
molecule that seems to be the nucleophile to attack the γ-phosphate. This is similar to the 
effect of GAPs on G-proteins, in which catalytic residues are provided by the partner 
across the dimeric interface (134).  
Dynamics of the FtsZ filaments 
           The stability of the FtsZ filament is weakened by the GTP hydrolysis, as 
inhibiting the GTPase activity (e.g. by depleting Mg2+) allows the fiber to persist (135, 
136). Factors modulating the GTPase activity, such as Mg2+, KCl and Ca2+, have 
profound effect on FtsZ dynamics (135, 136). Some data suggest that FtsZ monomers 
within a filament are predominantly bound with GDP (probably in the form of GDP:Pi). 
(123) Therefore, the mere hydrolysis of GTP does not ensure the depolymerization and it 
has been suggested that one or a few layers of GTP containing subunits at the end of the 
FtsZ filament might be sufficient to stabilize the whole structure (123), similar to the 
GTP cap in microtubules (129). However, a more recent study suggests that the FtsZ 
filament is predominantly GTP bound, which indicates that the hydrolysis of GTP might 
be the rate-limiting step for filament dissociation instead (137).  
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Proteins interacting with FtsZ 
           As the Z-ring is the central apparatus for the cell division, it is not surprising that 
many proteins make interactions with FtsZ. They may either play some roles in 
regulating the Z-ring assembly or have their own functions in the cell division (Figure 
29a). 
           There are two types of Z-ring regulators: the inhibitor and the stabilizer. 
Important Z-ring inhibitors include MinC, as already described. Another important 
inhibitor is SulA, a protein induced by SOS-response when DNA damage is encountered 
(132). It binds to FtsZ at the T7 loop containing face and forms an elongated complex 
Z:A:A:Z (Z for FtsZ and A for SulA). This caps the FtsZ filament, preventing it from 
further growth (Figure 30a) (132). A third negative regaulaor is EzrA in B. subtilis, a 
membrane anchor conserved in several Gram-positive bacteria (122). The Z-ring 
stabilizers include FtsA, ZipA and ZapA. FtsA is an actin homolog that interacts with 
the C-terminal region of FtsZ. To ensure the proper cell division, a cellular FtsA to FtsZ 
ratio at about 1:100 is maintained (138). ZipA is a membrane protein that contains 
motifs common to microtubule-associated proteins. Like FtsA, it interacts with the C- 
terminal tail of FtsZ. A crystal structure of the complex formed by ZipA and C-terminal 
17 residues of FtsZ shows that the FtsZ C-terminal tail forms a β-strand followed by an 
α-helix and binds in a shallow and hydrophobic cavity in the ZipA C-terminal domain 
(Figure 30b) (139). ZapA is another Z-ring stabilizer. It is a small protein largely 
composed of coiled-coil and can dimerize or tetramerize, which probably crosslinks 
several FtsZ polymers (140). 
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Figure 29 Composition and Constriction of the Z-ring. 
 
a. Proteins Interacting with the Z-ring 
 
b. Mechanism of the Z-ring Constriction 
Constriction is triggered by the transition of the FtsZ filament from straight to 
curved (1) or the depolymerization (2) of the FtsZ filament. 
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           Other division proteins, not directly involved in the Z-ring stability, are also 
recruited to the Z-ring, either directly by binding to FtsZ or indirectly by interacting with 
FtsZ binding proteins. Examples include DNA condensing protein MukB (113) and 
nucleoid occlusion protein SlmA (117). Components of the septum cell wall 
biosynthesis machinery, such as FtsW, FtsI, FtsN and AmiC, are also recruited (118). It 
is generally accepted (118) that FtsW is recruited first, followed by FtsI, a tranpeptidase. 
FtsI then recruits FtsN that further recruits AmiC. AmiC cleaves the peptide moiety from 
N- acetylmuramic acid on the cell wall and allows the cell division to proceed, while 
FtsN may function as a mechanic linkage connecting the septum ring to the cell wall 
(118).  
           FtsW is a membrane bound protein conserved among most bacteria and contains 
10 transmembrane helices (118). In addition to the recruitment of FtsI, it also plays a 
role in translocating lipid-linked precursors for cell wall synthesis (118). It is unclear 
how FtsW itself is recruited to the Z-ring. In M. tuberculosis, FtsW processes a unique 
C-terminal extension that interacts with the C-terminal tail of FtsZ (141). It seems that in 
M. tuberculosis, FtsW can directly bind to FtsZ (141). Since neither FtsA nor ZipA is 
present in M. tuberculosis, FtsW might provide an alternative mechanism for the Z-ring 
stabilization and membrane attachment in this organism.  
Questions regarding the in vivo function of the Z-ring  
           The architecture of the Z-ring still remains elusive. It has been suggested that a 
sheet of FtsZ polymer encircles the cell, which requires each FtsZ fiber to be able to 
span the whole circumference of the mid-cell and is not supported by available  
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Figure 30 Structures of FtsZ in Complex with Accessory Proteins. 
 
a. The Complex between FtsZ and SulA  
 FtsZ is shown in cyan and the SulA dimer is shown in golden.  
 
b. The Complex between ZipA and the FtsZ C-terminal Domain 
ZipA is shown in golden. The FtsZ C-terminal domain forms an α-helix and a β-
strand and colored in cyan. The surface is colored according to the electrostatic 
potential as was described earlier.    
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experimental data (142). More recent studies suggest that the Z-ring may be constructed 
by the alignment of many short filaments, either by forming lateral interaction directly 
between filaments or by FtsZ binding bridging proteins (142, 143). This seems to be 
more likely, as it does not require a long FtsZ filament as suggested from the first model. 
In vitro observation also reveals that the FtsZ filament have various curvatures, from 
straight fibers to helical tubes, as described earlier. However, the curvatures of the 
filaments in vivo remain elusive (142, 143). 
         It is known that at the late stage of cytokinesis, the Z-ring undergoes constriction. 
What is the mechanism for constriction? Several models have been suggested. One 
hypothesis involves the transition from the GTP bound, straight FtsZ filament to the 
GDP bound, curved FtsZ filament (144) (Figure 29b). However, it is unclear whether 
this type of transition in filament geometry can provide enough force. Another 
hypothesis suggests that the aligned short FtsZ filaments may slide onto each other, 
driven by unknown motor proteins, as the myosin and actin do in muscle cells (142). 
This requires a discovery of unknown motor proteins, which has not been made yet. In a 
third model, the constriction is suggested to be triggered by the depolymerization of the 
FtsZ filament, as has been demonstrated in microtubules (142) (Figure 29b). Finally, the 
FtsZ filament might simply be a passive player, as the inward growth of the 
peptidoglycan may provide the major force for the Z-ring constriction (118). 
Significance of This Work 
           Although much progress has been made in FtsZ, the structure of the FtsZ filament 
remains inconclusive. It has been proven that FtsZ can adopt the tubulin-like straight 
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filament under most in vitro experimental conditions. However, the nature of the helical 
filaments that have also been observed in many circumstances is unclear. In addition, the 
mechanism of FtsZ polymer disassembly, induced by GTP hydrolysis and the γ-
phosphate release, also remains elusive. These questions need to be addressed first 
before we are able to find answers for questions that are more biologically relevant, such 
as the Z-ring assembly and dynamics. In the next chapter, we will present a structural 
biology study that sheds light on the structure of helical filaments and the possible 
mechanism of FtsZ polymer dissociation.  
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CHAPTER V 
STRUCTURAL STUDY OF AN FTSZ CRYSTAL FILAMENT 
Methods 
Cloning and purification of FtsZ 
           The full-length M. tuberculosis FtsZ was cloned and purified by our collaborator 
Lucile White from Southern Research Institute by following the published protocol 
(135). Selenomethionine substituted FtsZ was produced using a similar protocol as 
stated in chapter III.  
           A truncated version of FtsZ (with the removal of the C-terminal region from 
residue 313 to 376) was also cloned as follows. The M. tuberculosis genomic DNA was 
used as the template. Each reaction (50 µl) contained 1 µg genomic DNA, 0.5 µl (25 
pmol) of each primer, 2.5 µl DMSO, 1 µl 10 mM MgSO4, 5 µl 10× thermal buffer (New 
England Biolabs), 10 µl 2.5 mM dNTP and 1 µl Deep Vent DNA polymerase (2 unit, 
New England Biolabs). The N-terminal primer had the following sequence: 5’-AGA 
GAA GCA TAT GAC CCC CCC GCA CAA C-3’, containing an NdeI restriction site 
(italic and bold). The C-terminal primer had the following sequence: 5’-CCC AAG CTT 
TTA TCA GAA GCC GGC CGC GAT CAC-3’, containing a HindIII restriction site 
(italic and bold) and a stop codon (bold and underlined). 30 cycles of PCR were 
performed with the temperature profile of 94 ºC for 30 seconds, 65 ºC for 30 seconds 
and 72 ºC for 90 seconds. There was also a 5 minutes at 94 ºC hot start step before the 
initiation of the PCR cycles and a 7-minute extension at 72 ºC after completion of the 
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PCR cycles. The PCR products were purified on a 0.8% agarose gel containing ethidium 
bromide and cloned into the pET28b vector. The construct was transformed into 
BL21(DE3) competent cell and verified by gene sequencing.  
           The truncated protein (designated as the FtsZ1-312) was expressed in Rossetta(DE3) 
E. coli strain. Cells were grown in LB medium at 37 ºC. When OD600 reached 0.5, gene 
expression was induced by 1 mM IPTG at 16 ºC for 20 hours and were then harvested 
and kept at -20 ºC. Cell pellets were thawed and protein purified using a Ni column, 
following the same protocol as described in Chapter III. The fractions containing the 
FtsZ1-312 protein were pooled, concentrated and dialyzed against buffer with 25 mM 
HEPES (pH 7.2), 100 mM NaCl, 1mM DTT, 0.1 mM EDTA and 10% glycerol. The N-
terminal his-tag was removed using thrombin (restriction grade, Novagen) by incubating 
45 µl thrombin (45 unit), 4.5 ml FtsZ1-312 (10 mg/ml), 1 ml 10× thrombin cleavage buffer 
(Novagen) and 4.5 ml dH2O at room temperature for 2.5 hours. The reaction mixture 
was then concentrated and loaded onto a superdex 75 size-exclusion column and eluted 
with 25 mM HEPES (pH 7.2), 100 mM NaCl, 1mM DTT, 0.1 mM EDTA and 10% 
glycerol. Fractions containing the FtsZ1-312 protein were eluted from a wide range, from 
aggregates to monomers.     
Polymerization test 
           The polymerization of FtsZ (both the truncated and full-length, 10mg/ml to 20 
mg/ml) is performed by mixing 20 µl FtsZ, 10 µl 100 mM GTP and 460 µl assembling 
buffer (100 mM MES pH 6.4, 100 mM NaCl, 12.5 mM MgCl2). Polymerization was 
verified by centrifuging the mixture at 100 K in a Beckman TLA100.3 rotor for 30 
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minutes at 4 °C. 100 µl of the supernatant was removed. The pellet was washed with 100 
µl assembling buffer and resuspended in 100 µl assembling buffer. Both the pellet and 
supernatant were analyzed using SDS-PAGE.  
           Polymerization results in a 90º rotation of light scattering and reduces the 
transmission light, which corresponds to an increase in the absorbance and can be 
directly measured by a conventional spectrometer in real time (142). 20 µl FtsZ was first 
mixed with 460 µl assembling buffer in a quazi cuvette. The background absorption at 
340 nm was monitored for 2 minutes. GTP was then added up to 40 µM and the 
polymerization of FtsZ was monitored by absorption at 340 nm for 15 to 60 minutes.   
EM analysis of FtsZ filaments 
           The FtsZ protofilament was produced by mixing 4 µl of 10 to 20 mg/ml FtsZ, 
with 4 µl of 100 mM GTP and 42 µl of assembling buffer. In addition, 0.2 to 1 mg/ml 
DEAE dextran or 10 mM CaCl2 was included in some experiments to study the effect of 
polycationic stabilizer or divalent cations on polymerization. The reaction mixture was 
left at room temperature for 10 minutes and was then diluted for 2 to 5 fold using the 
assembling buffer before making grids and being sent for EM analysis (the last two steps 
were performed by Christos Savva from the Department of Biology). 
Crystallization 
           The full-length FtsZ protein (10 mg/ml) was incubated with 2 mM GDP and 
10mM EDTA for 1 hour on ice before setting up the crystallization reaction. Crystals 
were grown using the hanging drop vapor diffusion method, with 1 µl protein mixed 
with 1 µl crystallization solution. The crystallization condition is 1.4 to 1.6 M (NH4)2SO4, 
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0.1 to 0.7 M NaCl, 0.1M HEPES pH 6.8 to 7.3 (145). Crystals appeared in 3 to 5 days to 
a size of 0.3 x 0.2 x 0.2 mm. Selenomethionine substituted proteins were crystallized 
under the same condition except with the inclusion of 10 mM DTT. 
           These crystals diffracted weakly at synchrotron to the resolution ranged from 4 to 
8 Å. Optimization trials using additives such as 10 mM ZnCl2 or 10 mM CaCl2 did not 
improve the diffraction power. Because this type of FtsZ crystal has a large unit cell with 
a high solvent content (about 0.68), a crystal dehydration protocol was tried by sealing 
the cover slip with a crystal containing drop over a reservoir well containing a higher 
concentration of  (NH4)2SO4 (2.5 to 3.5 M) and allowing to equilibrate for 2 to 3 days. 
Although there was no visible crystal deterioration, diffraction power was lost. As FtsZ 
has an unstructured C-terminal region, therefore we tried to crystallize the truncated 
protein (FtsZ1-312), under the same crystallization condition. Though it crystallized faster 
than the full-length protein, it diffracted only to the same resolution and its spots were 
highly smeared and data processing was not possible. This is most likely due to less 
order in the crystal.  
Heavy atom soaking  
           Heavy atoms soaking was also attempted to improve crystal diffraction and 
provide experimental phase information that is unbiased by the model. In order to 
identify heavy atoms capable of binding FtsZ, compounds were incubated with the FtsZ 
sample at room temperature for 30 minutes in the presence of the crystallization solution. 
Samples were then analyzed by a native PAGE (146). Four mercury compounds, 
including HgCl2, ethyl mercuric phosphate, p-aminophenyl mercuric acetate and  
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Figure 31 Use of Native PAGE to Screen Heavy Atoms. 
 
Lane 1:  No heavy atom 
Lane 2:  Sodium Tungstate 
Lane 3:  Potassium Tetracynaoplatinate (II) 
Lane 4:  Samarium (III) Chloride 
Lane 5:  Mercury (II) Chloride 
Lane 6:  Lead (II) Acetate  
Lane 7:  Potassium Hexachloroiridate (IV) 
Lane 8:  Ammonium Tetrachloroplatinate (III) 
Lane 9:  Sodium Hexachloroplatinate (IV) 
Lane 10: Ethyl Mercuric Phosphate 
Lane 11: Triethyl Lead Acetate 
Lane 12: Europium (III) Chloride 
Lane 13: PIP 
Lane 14: Thimersol 
Lane 15: p-aminophenyl mercuric acetate  
 
thimersol, led to a shift of the protein band on the native PAGE, indicating the binding 
of the heavy atom to the protein (Figure 31).  Among them, thimersol was the only one 
that did not visibly damage the crystal, and thus, crystals were soaked with 2 mM 
thimersol for about 20 hours and one dataset was collected to 5 Å. But no heavy atom 
was found by reviewing either the difference Patterson map or the F0-Fc map. One 
possible explanation is when the pH is above 6.0, (NH4)2SO4 can release NH3 that, as a 
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good nucleophile, will compete with protein for heavy atoms. Attempts were made to 
transfer the crystal into new drops that contain PEG instead of ammonium sulfate, but 
crystals invariably got damaged. 
Data collection and crystallographic methods 
           Crystals were soaked into the mother liquor containing 20% to 25% glycerol 
before being flash cooled to 100K for data collection. Both a native dataset and a three 
wavelength MAD dataset (peak, inflection and low energy remote, at 0.97912, 0.97934 
and 1.00531 Å, respectively) were collected at 14IDB at APS. For each dataset, the data 
were collected with a half-degree oscillation and a crystal to detector distance at 300 to 
400 mm. A range of 90˚was collected for the native dataset. For the MAD data, angle of 
180˚was collected.  
           The data were processed with HKL2000 (Table 14). The space group is P6(4)22. 
Both the native and MAD data showed good statistics up to 4.0 Å. However, the MAD 
data had low completeness (less than 40%) at resolutions higher than 4.6 Å. The 
molecular replacement was performed in MOLREP and EPMR, while the MAD phasing 
was done using SHARP. The model building was performed in XtalView. The model 
was refined in programs CNS, CORRELS and REFMAC.              
Results and Discussion 
The polymerization of FtsZ 
           The ability of FtsZ to form polymers was analyzed. Pelleting assay showed most 
FtsZ was retained in the supernatant fraction when GTP was omitted. After the addition 
of 2 mM GTP, most FtsZ was in the pellet fraction, indicating the polymer formation 
  
134
(Figure 32a). Monitoring absorption at 340 nm suggested that the polymerization of FtsZ 
clearly reassembled a two phase process. There was a rapid phase, in which the 
absorbance quickly reached the half height of the maximum and lasted for about 60 
seconds. Followed was a slow phase, when the absorbance continued to increase for 
about one hour. (Figure 32b) This phenomenon is in agreement with the published data 
collected by directly monitoring the scattering light (135).  
           The FtsZ filament was observed under EM (Figure 33a). Each filament seems to 
be composed of two dense regions separated by a gap. The dense region is probably 
corresponding to a single FtsZ protofilament (Figure 33b). The width across whole 
filaments is about 90 Å and that for the gap is about 20 to 30 Å. If polycation stabilizers 
like DEAE-dextran or divalent cation such as Ca2+ were present, extensive bundling 
could be formed, which may suggest that these compounds induce more lateral 
interactions. These observations are consistent with those made in FtsZ fibers from other 
sources (124, 125, 147). The polarity of these protofilaments is unclear, though there are 
reports suggesting that they are in parallel (125, 147). And the putative lateral interaction 
interface has been (125). However, this has not been supported by mutation studies (148).  
           E. coli FtsZ was reported to form a helical shaped filament under the condition of 
GDP and DEAE-dextran (127). From this study, however, we found that the M. 
tuberculosis FtsZ did not polymerize under this condition. Instead, massive aggregation 
was identified under EM (data not shown). Published studies in the E. coli FtsZ also 
suggested that GDP (without DEAE-dextran) could destabilize pre-formed E. coli 
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Table 14 Data Collection Statistics of FtsZ Crystals. 
 
 
 Native    Peak Inflection Low Energy Remote 
  
Space Group P6(4)22 P6(4)22 P6(4)22 P6(4)22 
Unit Cell Parameters  
a, b, c (Å ) 
α, β, γ (º) 
131.24, 131.24, 328.27 
       90.0, 90.0, 120.0 
131.09, 131.09, 327.78 
       90.0, 90.0, 120.0 
131.56, 131.56, 328,49 
       90.0, 90.0, 120.0 
131.86, 131.86, 328.99 
       90.0, 90.0, 120.0 
Wavelength (Å ) 0.90000 0.97912 0.97934 1.00531 
Resolution Range (Å ) 50.0-3.90 50.0-3.90 50.0-3.90 50.0-3.90 
Rsym  0.071 0.074 0.065 0.052 
Completeness (%) 99.4 58.6 57.2 61.0 
I/σ(I) 38.4 23.7 24.2 26.0 
MAD Figure of Merit                                                                                    0.43 
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Figure 32 Polymerization Assay of the Full-length FtsZ. 
 
a. The supernatant (S) and pellet (P) after ultracentrifugation of the FtsZ sample with (+) or without (-) 2 mM GTP 
 
b. The time course of FtsZ polymerization monitored by absorbance at 340 nm 
 
c. The time course of slow FtsZ filament disassembly after the addition of GDP monitored by absorbance at 340 nm 
 
d. The time course of polymerization of FtsZ was monitored by absorbance at 340 nm after being pre-incubated with 0 µM 
GDP (1), 100 µM GDP (2) and 2 mM GDP (3) 
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Figure 32 Continued.  
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Figure 33 EM Images of FtsZ Filaments. 
 
a. The filaments formed by the full-length FtsZ 
 
b. The enlarged image from (a) showing the morphology of a single full-length FtsZ filament 
 
c. The filaments formed by the truncated protein FtsZ1-312 
 
d. The enlarged image from (c) showing the morphology of a single FtsZ1-312 filament 
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Figure 33 Continued.  
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FtsZ filaments and pre-incubation of FtsZ with GDP would prevent the formation of 
polymers by the subsequent addition of GTP (123). Our studies on the M. tuberculosis 
FtsZ suggested that by adding GDP, up to 2 mM, into the preformed FtsZ filament, we 
observed a slow decrease in the absorption at 340 nm (Figure 32c). Compared with the E. 
coli data, the destabilization (if any) effect is much slower, which may be consistent with 
the reported slow kinetics of the M. tuberculosis protein (135). Pre-incubation of the M. 
tuberculosis FtsZ with GDP, however, indeed inhibited the polymerization in a 
concentration dependant manner. 2 mM GDP was sufficient to completely block the 
formation of polymers, judged from monitoring the absorbance change (Figure 32d). 
When GDP concentration is lowered to 100 µM, polymerization was allowed at a slow 
rate (Figure 32d). Based on these data, we conclude that GDP is a destabilization agent 
for the M. tuberculosis FtsZ filament.  
Structural solution of the FtsZ crystal filament 
           Crystal structures from the M. jannaschii, P. aeruginosa and M. tuberculosis FtsZ 
(Table 13a) were used as models for molecular replacement trials in MOLREP. The 
structures of the M. jannaschii and P. aeruginosa FtsZ did not give any solutions. The 
crystal structure of the M. tuberclosis FtsZ shows a novel dimer composed of two 
molecules adopting different conformations. One molecule is in the “open” form that 
binds the ligand GTP-γ-S, while the other one is in the “closed” form in which the GTP 
binding site is empty. Although the dimer and the “closed” molecule did not give 
molecular replacement solutions, using the “open” monomer as the model, we found one 
solution composed of two monomers with an R factor of 0.540 and a correlation 
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coefficient of 0.324. During the process of molecular replacement, both space groups 
P6(2)22 and P6(4)22 were tried and only the later one led to a correct solution, 
confirming the proper space group is P6(4)22. A 2Fo-Fc electron density map calculated 
based on this solution clearly showed the secondary structural elements. However, the 
packing of the model, as well as the high R factor, indicated that there should be at least 
one more molecule in the asymmetric unit.  
           By superimposing the “open” and “closed” molecules of the original FtsZ dimer, 
large structural variations were identified, particularly loops in the N-domain near the 
nucleotide binding pocket. These regions also correspond to poor electron densities from 
the 2Fo-Fc map calculated using the partial model. We assumed these regions in the 
model were different from the actual crystal structure. Therefore, they were deleted from 
the model and the revised model was used for a new around of molecular replacement in 
EPMR to find the third molecule. The structure was refined using the rigid body 
refinement protocol in REFMAC and the R factor was lower than 0.50.  
           In order to obtain more phase information, MAD phasing was tried. However, 
due to the low resolution, the anomalous signal from the crystal was low. The anomalous 
signal to noise ratio calculated from XPREP was less than 1.5 as the resolution was 
higher than 6.0 Å. We were not able to find correct heavy atom positions either using the 
Patterson search or direct methods. However, an anomalous difference map, calculated 
based on the phases from the refined molecular replacement solution and the anomalous 
difference from the peak dataset, showed strong positive densities around the sulfur sites 
of some methionine residues (Figure 34). In all, 24 potential selenium sites with 
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densities contoured above 5 σ were found per asymmetric unit. Among them, 20 
selenium sites were manually built into densities contoured above 8 σ and this 
constellation of anomalous scatterers was used for protein phasing in SHARP. At first, 
all three wavelengths were used. However, we failed to refine heavy atom sites using 
this data. Later on, it was found that the low energy remote dataset was problematic, 
probably because it had little anomalous signal.  Therefore, only the peak and inflection 
datasets were used and the B factors of heavy atoms were constrained at 60.0 during the 
refinement. The refined selenium atoms were inspected and were seen restrained near 
their original locations, with satisfactory occupancy (only one atom had very low 
occupancy, at 0.07). The final figure of merit was 0.43.   
           The 2Fo-Fc map based on the molecular replacement phases was sufficiently well 
defined so most secondary structures were recognized (Figure 35). In comparison, the 
MAD phases were relatively poor even after solvent flattening and NCS averaging in 
DM, although interpretable densities corresponding to secondary structures could be 
recognized. Maps based on the combination of the MAD and molecular replacement 
phases were more useful because they showed improved density in some regions. For 
example, using the combined phases the map showed a density corresponding to the 
loop from residues 172 and 173 in the molecule A that was missing in the 2Fo-Fc map. 
Combination of the MAD and molecular replacement phases were performed in 
SIGMAA. Phase extension, density modification and multiple-crystal averaging were 
then performed in DMMULTI (149). We also tried to further improve the map by using 
B-factor sharpening, which was suggested as useful for low resolution data (150).   
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Figure 34 Anomalous Difference Map. 
 
The densities corresponding to anomalous scatterers are shown in golden 
contoured at 5 σ. The methionine residues are also displayed.  
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Figure 35 Electron Density Map for FtsZ. 
 
The 2Fo-Fc map contoured at 1 σ is shown. The main chain of the FtsZ model is also 
displayed. This region corresponds to the large β-sheet in the C-terminal domain of 
FtsZ. 
 
Basically, a negative B-factor (-100 to -200) was applied to each amplitude of the MAD 
data by CAD. The modified amplitudes were subsequently used for map calculation. 
However, this procedure does not lead to significant improvement on the electron 
density map of FtsZ. 
            Rebuilding of the model was performed in regions where the correct electron 
density for protein structure was unambiguous. The final Fo-Fc map showed a density 
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above 3σ near the residue Phe 180. As this was the nucleotide binding site and this 
density resembled a GDP, it was recognized and fit with a GDP molecule (Figure 36a). 
The major problem for refinement was the low data to parameter ratio, intrinsic to the 
low resolution diffraction data. Initially, the refinement was mostly restricted to the rigid 
body refinement, by which we were able to drop R and Rfree factors to 0.38 and 0.43, 
respectively. We later found that the model could be restrained properly by applying a 
very low X-ray term weighting factor (0.001 vs. 0.3 as the default) and tight geometry 
restrains (restrains for bond distance, bond angle and plane at 20, 5 and 40, respectively 
vs. 1, 1 and 1 as the default). NCS restrains were also applied. This protocol allows for 
the restrained refinement being carried out in REFMAC, which decreased the R factor 
and Rfree factor to 0.29 and 0.38, respectively. The final model shows an average B 
factor at 169.4 Å2.  Such a high B factor was also observed in several other low 
resolution crystal structures, such as the E. coli ABC transporter MsbA (1JSQ), S. 
lividans K+ channel KcsA (1BL8) and SIV gp120 envelope glycoprotein (2BF1), and 
may contribute to the rapid decrease in diffraction intensities as the resolution was 
increased beyond 4.0 Å in our crystal. 
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Table 15 Refinement Statistics of FtsZ. 
 
No. of Atoms/Residues  
Protein 
Ligand 
841
3
Maxium Resolution (Å) 4.0
Rwork 0.294
Rfree 0.377
Average B factor (Å2) 169.42
r.m.s.d from Ideal Geometry 
Bond Distance (Å) 
Bond Angles (º) 
0.004
3.375
Ramachandran Plot (%) 
Favored 
Allowed 
Generously Allowed 
Disallowed 
34.3
42.1
16.0
7.6
Model Figure of Merit 0.61
 
 
 
 
  
147
 
 
 
 
Figure 36 The GDP Binding Site.  
 
a. The Fo-Fc Map (Purple Contoured at 2 σ Level and Green at 3 σ  
Level) near Phe 180 Fit with One GDP Molecule 
 
b. The Accessible Surface of the Curved Dimer   
 
c. The Accessible Surface of the Straight Dimer   
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The overall crystal structure 
           The final statistics are in Table 15. There are three FtsZ molecules arranged head 
to tail in each asymmetric unit. Each molecule contains residues up to Gly 311 or Phe 
312. Residues after that are disordered in the absence of accessory proteins, as in all 
reported FtsZ structures. In general, the electron density map for the N-domain (residues 
1 to 161) is poorer than that for the C-domain (residues 162 to 312). Consequently, the 
model is more complete for the C-domain. Particularly, poor densities are identified 
around residues 34 to 41, 9 to 17, 60 to 70 and 94 to 103. These regions are around the 
GTP binding site and may be involved in conformational switch (see below).  
           By applying the crystal symmetry, a left-handed antiparallel continuous double 
helical crystal filament with the diameter about 131 Å has been constructed. Its diameter 
is the same as the a and b axises of the crystal unit cell, as filaments are arranged in 
parallel to these axises. The surface of the helical tube is negatively charged. Its pitch is 
around 130 Å, with six molecules for each turn. Between two strands of the double 
helical filament, there is a gap of about 20 Å and no direct contact between 
protofilaments has been identified (Figure 37a, b). 
           In order to get more insights into the crystal filaments, we have looked into the 
literature. Many proteins can form filaments and several of them have been characterized 
by crystallography. For example, the DNA recombination protein RecA forms a right-
handed helix, with its pitch about 65 to 95 Å. Interestingly, the pitch of the RecA 
filament depends on the liganded state of this protein, as the ADP bound fiber shows a 
shorter pitch and the ATP bound fiber shows a longer one (151). Tubulin can also form  
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Figure 37 The Double Helical Structure of the FtsZ Crystal Filament. 
 
a. The top-down view 
 
b. The side view  
 
In both views, the two strands are colored in cyan and golden, respectively. The 
diameter and pitch of the helix are labeled.  
 
 
the helical filament. The 4 Å crystal structure of the tubulin:stathimin-like domain 
complex  shows that the tubulin forms a curved filament corresponding to part of a 
shallow helix with a 400 Å pitch (152) (Table 13b). The SAM domain of the 
transcription repressor TEL is another example. It can form a helical filament with a 
pitch of 53 Å and a diameter of 83 Å (153). In summary, these results suggest that the 
helical filaments are regularly observed in crystal structures and the geometry of the 
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FtsZ helical crystal filament reported here is within the range of other helical filaments 
characterized so far.   
The dimeric interface   
           The dimeric interface of the M. tuberculosis FtsZ is formed with residues 160 to 
170, 133 to 137 and 171 to 175 from one molecule and residues 270 to 280 from its 
neighboring molecule. As it forms part of the helical filament and may correspond with 
the curved fiber observed from EM, we will refer the dimer observed in our crystal 
structure as the curved dimer. The recent reported M. jannaschii FtsZ dimer is part of a 
semi-continuous straight filament (Table 13a) and thereby will be referred as the straight 
dimer. The difference between these two types of dimer can be visualized by 
superimposing one monomer of each dimer, as a large rotation (about 60˚) can be 
observed between the second monomers (Figure 38a). Importantly, the T7 loop of the 
curved dimer (around residues 205 to 210) does not make contact with the nucleotide 
binding site of its neighboring molecule (Figure 38b), while the T7 loop of the straight 
dimer (around residues 232 to 237) does (Figure 38c). Actually, in the curved dimer, the 
Cα of the residue Asp 210 is about 20 Å away from the β-phosphorus of the bound GDP, 
while in the straight dimer, the distance between the Cα of the equivalent residue Asp 
235 and the β-phosphorus of the bound GTP is about 11 Å, which demonstrates the 
exclusion of the T7 loop from the nucleotide binding pocket in the curved dimer. 
Biochemical data suggest that the T7 loop from one monomer should interact with the 
nucleotide binding pocket of its neighboring monomer, in order to form the intact 
GTPase active site (133). Crystallographic data in the straight FtsZ and tubulin dimers  
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Figure 38 The Difference in the Dimeric Interface between the Curved and Straight Dimer. 
 
 
a. Comparison of the Curved and Straight FtsZ Dimer  
The curved (cyan) and straight (red) FtsZ dimers are aligned at the bottom monomer.  The T7 loop is colored in blue and 
golden in each dimer, respectively.  The displacement of the T7 loop is indicated by the arrow.  
 
b. The detailed view of the dimeric interface within the curved FtsZ dimer 
The distance between the Cα of the residue Asp 210 and the β-phosphorus of GDP is indicated. And the T3 (disordered, 
represented by black dashed line) and T7 loops are indicated by black arrow. The residues on the T7 loop are also displayed.  
 
c. The detailed view of the dimeric interface within the straight FtsZ dimer 
The distance between the Cα of the residue Asp 235 and the β-phosphorus of GDP is indicated. And the T3 and T7 loops are 
indicated by black arrows. The residues on the T7 loop are also displayed.  
 
d. Comparison of the Curved and Straight Tubulin Dimer 
The curved (red) and straight (white) tubulin dimer are aligned at the bottom monomer. The T7 loop is colored in cyan and 
golden in each dimer, respectively. The displacement of the T7 loop is indicated by the arrow.   
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support this mechanism (131). However, this is not present in our structure. Therefore, 
we propose that the helical filament we observed is in an “off” state, when the GTPase is 
inactive.  
The GDP binding site   
           A GDP molecule is bound to the nucleotide binding pocket and its guanosine ring 
appears to be stacked with the aromatic side chain of Phe 180. The regions around the 
GDP binding site correspond to the worst electron density. As mentioned in earlier, 
many loops in this region do not have the well defined density. What is the cause of this 
problem? As published by Leung, et al. (130), this region is flexible and contains 
structural elements that are similar to the switch I and II in G-proteins whose 
conformation are dependent on the liganded state of the nucleotide. Particularly, the T3 
loop (residues 60 to 70) is ordered only when the γ-phosphate group is present. 
Therefore, in the GDP bound protein, as shown from this study, this loop is disordered 
and cannot be found in the electron density. Other loops around this pocket might take 
different conformations from those in the model for molecular replacement, as it was 
originally derived from the GTPγS bound FtsZ monomer. If we have data to a higher 
resolution, we might be able to see some of the densities in this region and have more 
clues on the nature of the conformational changes. 
           After calculating the solvent accessible surface, the nucleotide binding pocket is 
found to be completely accessible to the solvent (Figure 36b). In the published straight 
FtsZ dimer (131), the GTP is mostly buried and accessible to the solvent only via an 
opening with a diameter of around 10 Å (Figure 36c). Though the 10 Å2 opening may 
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still be enough for nucleotide to diffuse into or out of the pocket (131), it is certainly 
more restricted. The biochemical studies to compare the accessibility of GTP and GDP 
bound filaments have not been reported. However, it was shown that that the helical 
shaped GDP bound filament was readily straightened after being washed with GTP 
(127), which indicated the GDP bound filament was fairly accessible to the solvent.  
The possible mechanism to destabilize the FtsZ and tubulin filament 
           Tubulin, the eukaryotic homolog of FtsZ, also forms straight and curved dimers 
(152). The curved form is induced by the binding of GDP as well as a Stathmin-like 
protein, a microtubule de-stabilizer (in Table 13b, 1Z2B, 1SA0 and 1FFX). By 
superimposing one monomer of each dimer, we see a similar shift of the second 
monomer, though with a much less degree than that in FtsZ. Similarly, the T7 loop is 
“pushed” out in the curved tubulin dimer, though different from the curved FtsZ dimer, 
in the curved tubulin dimer the T7 loop is never completely out of the nucleotide binding 
pocket (Figure 38d). 
           The buried surface area of the curved tubulin dimer is about 1960 to 2200 Å2, 
smaller than that of the straighter tubulin dimer (about 3000 Å2). In FtsZ, the buried area 
within the curved FtsZ dimer (1100 to 1350 Å2) is also significantly smaller than that of 
the straight FtsZ dimer (about 2344 Å2). The decrease of the buried surface area 
probably correlates with the destabilizing effect by Stathmin (in tubulin) and GDP (in 
tubulin and FtsZ).   
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Figure 39 The Putative Mechanism for FtsZ Dynamics. 
     
 
           In the straight dimer of FtsZ, the T3 loop (around residues 93 to 98) is in close 
contact with the T7 loop (Figure 38c). In the curved dimer, the T3 loop (residues 60 to 
70) is disordered (Figure 38b), as was reported earlier (130). Therefore, it is possible that 
the release of γ-phosphate group may trigger the conformation change of the T3 loop, 
which may lead to the reorganization of the protein-protein interface. For example, some 
dimeric interactions, such as those between the T3 and T7 loops, may be abolished. As 
the result, it might be energetically more stable for the individual FtsZ monomers to be 
re-oriented to form the helical filament (Figure 39). 
           As in contrast with the GTPase “on” state of the straight filament, we regard this 
helical FtsZ filament as GTPase “off”. What is the fate of this helical filament? As it 
forms under the presence of a destabilizing agent (GDP) and has a decreased buried      
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Figure 40 The Potential Role of the C-terminal Tail. 
 
a. The Putative C-terminal Tail Location 
The last residues of each monomer in neighboring strands are displayed. Their 
distance is labeled. The two neighboring strands are colored differently (cyan and 
golden, respectively).  
 
b. A Model for Lateral Interaction  
Proposed by Lowe et al. (125) based on EM observation of an FtsZ sheet, two 
parallel protofilaments form a thick filament. Thick filaments are arranged in anti-
parallel. Though tighter contacts were proposed for interactions within a thick 
filament, the interactions between thick filaments are much less and were proposed 
to involve the C-terminal tail region (labeled as “C”).  
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surface area, the helical shaped FtsZ filament probably represents a less stable state. 
Therefore, it might eventually undergo disassembly.    
The probable role of the C-terminus 
           Interestingly, the C-terminal residues (Gly 311 or Phe 312) on antiparallel strands 
of the neighboring protofilaments are pointing to each other with a distance of about 30 
Å (Figure 40a). As mentioned earlier, the last 67 residues (residue 313 to 379) of FtsZ 
are disordered. It is reasonable to speculate that this part of the structure occupies the 
gap region between the neighboring strands and makes contacts. Actually, in the Ca2+ 
induced FtsZ sheet reported by Lowe, et al. (125), the C-terminal tail between two 
antiparallel thick filaments did interact (Figure 40b).      
           To investigate the role of the C-terminal tail, we tested the polymerization of the 
truncated protein FtsZ1-312. It polymerized similarly to the full-length FtsZ, which 
indicated that the C-terminus of FtsZ was not directly involved in the polymerization. 
Visualized by EM, we found that the FtsZ1-312 filaments showed more bundling (Figure 
33c) than the filaments formed by the full-length protein. Furthermore, the individual 
FtsZ1-312 filament did not have the feature of two dense regions separated by a clear gap, 
as was demonstrated from the full-length FtsZ filaments (Figure 33d). 
           Based on our data, we hypothesize that the unstructured C-terminal plays a role in 
modulating the lateral interaction between the FtsZ filaments. Removal of this region 
seems to promote bundling, probably because the truncated protein forms a more tight 
lateral interaction. In the cell, the C-terminal tail is involved in the binding of accessory 
proteins (e. g. ZipA and FtsA). Their binding usually triggers bundling of FtsZ filaments 
  
157
and also stabilizes the Z-ring (126). It will be interesting to further investigate this part 
of the structure and their role in the filament interactions. 
Conclusion 
           The polymerization and de-polymerization process is critical for the proper 
function of FtsZ. In this chapter, we find the M. tuberculosis FtsZ can form a left-handed 
double helical crystal filament. In contrast to the straight filament reported earlier, our 
findings show the catalytic T7 loop is not in the nucleotide binding loop, which suggests 
a GTPase inactive form. Furthermore, the helical filament we observed has a smaller 
buried surface area than the straight filament, which may indicate it is less stable. 
Therefore, we argue for a mechanism for FtsZ destabilization by GDP, in which the loss 
of the γ-phosphate group triggers conformational changes in the nucleotide binding 
pocket and then leads to the re-organization of the dimeric interface. The result is to 
form a GTPase “off” helical filament that is energetically less stable and may be the first 
step for the disassembly of the FtsZ polymer. We also describe the tentative role of the 
flexible C-terminus and its possible contribution in modulating the lateral interaction. 
Consistent with our crystal structure and EM observations reported by other groups, the 
C-terminal tails may make contacts between two antiparallel strands. However, the 
biological relevance of this type of interaction is unclear. To sum up, we think our 
discoveries will provide a testable hypothesis that may deepen the understanding of the 
FtsZ polymerization.  
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CHAPTER VI 
GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
           Crystallography is a powerful technique to investigate a biological system. It 
provides a static atomic image of the macromolecule that can be the basis for further 
analysis. For complete understanding of the scientific problem, however, hypothesis 
made from the information gained by crystal structures should be verified by perturbing 
the system. Therefore, the combination of both crystal and solution methods will be the 
most suitable approach. In this dissertation, we applied both crystallographic and 
biochemical techniques onto MVK and FtsZ. Our results provided a detailed picture on 
how these two proteins function and are summarized as follows.  
           The work on MVK established the fold of MVK within the GHMP kinase family 
and the structural basis for the substrate binding, catalysis and inhibition of this enzyme. 
Our data revealed the important role of the phosphate-binding loop, in binding of 
nucleotide and terpenoid ligands. We also explored the nucleoside base binding pocket 
and both the selectivity and degeneracy of this pocket was demonstrated. Our studies on 
terpenoid inhibitors explained how these compounds compete with ATP. The potential 
mechanism on why these compounds are uncompetitive with mevalonate was proposed 
as mevalonate might facilitate the ordering of the carbon chain of terpenoids. Though we 
did not directly solve the location of mevalonate in the crystal structure, our analysis of 
water structures near the catalytic pair Asp 155-Lys8 revealed the putative location of 
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the phosphoryl acceptor and helped to model a mevalonate into the active site. Finally, 
the possible catalytic mechanism was proposed based on our structural data. 
           In order to further investigate the binding mechanism of MVK, as well as provide 
lead inhibitors for drugs design, we performed virtual screening on this protein. This 
study produced two compounds that showed limited inhibition to MVK. However, the 
whole designing process was far from a success. Their inhibition to MVK was low and 
no improvement could be achieved by optimization steps. Using our current active site, 
compounds are routinely docked to the phosphate-binding loop, which may causes weak 
inhibition, low specificity and poor scoring accuracy.  
           The work on FtsZ revealed a novel helical filament that was different from the 
straight filament reported by Lowe’s group (131). This filament might correspond with 
the helical shaped filament of the E. coli FtsZ in the presence of GDP and DEAE dextran 
(127). Our findings also indicated that the catalytic T7 loop is not in the nucleotide 
binding pocket, in contrast with the straight filament. Therefore, we proposed that our 
observation might resemble a GTPase “off” state. GDP was demonstrated as a 
destabilizer of FtsZ polymers and the helical filament in our structure has less buried 
surface area than the reported straight filament. Therefore, we hypothesized that the 
conformational changes in the nucleotide binding pocket triggered by GTP hydrolysis 
might lead to the re-organization of the dimeric interface, which could result in the 
straight to helical transition in the overall filament and create a less stable helical fiber 
that may be the intermediate for further disassembly.  
  
160
           We also investigated the role of the FtsZ C-terminal tail. This region is 
unstructured in all available crystal structures of FtsZ and is involved in the interaction 
with many FtsZ accessory proteins. From our structure, we inferred that this region may 
be involved in the interaction between two anti-parallel strands. Removal of this tail still 
permitted polymerization, though more bundling was observed from filaments formed 
by the truncated FtsZ. The exact role of the C-terminal tail of FtsZ is still unclear. In this 
dissertation, we proposed that it might modulate the lateral interactions of neighboring 
FtsZ filaments during the assembly of the Z-ring. 
           Our work not only provided insights onto these interesting proteins, but also 
raised more questions. It is certain that more studies can be performed in the future to 
further the understanding in this area.  
           For MVK, we would like to solve the crystal structure with both mevalonate and 
terpenoid bound to it. As we discussed in Chapter III, with the presence of mevalonate, 
the carbon chain of the terpenoids might be ordered and any conformational changes, 
such as the active site pocket closure, might be observed. Currently, only the dioxane 
condition produces diffracting crystals. As dioxane is likely to compete with mevalonate, 
a crystallization condition independent of dioxane should be identified. We indeed have 
several conditions using PEG as the precipitant. However, they only produce thin 
needles that do not diffract. Additive screening and extensive optimization have been 
performed without much success. Certainly, more optimization or crystallization 
screening should be performed. Secondly, more virtual screening can be performed to 
identify better inhibitors. We currently have a grid based computing system that can be 
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used to screen one million compounds in a reasonable time frame.  In addition to screen 
for larger database, we should also explore the binding site distinctive from the 
phosphate-binding loop, because of the problems already being discussed. If the 
terpenoid carbon chain binding site can be determined by crystallography, that region 
will provide an attractive target. Compounds designed to bind to this region will be more 
hydrophobic and do not need to compete with the phosphate groups directly, which may 
lead to the improvement in both inhibition and specificity.  
           Our analysis on the FtsZ helical filament raised the question regarding 
conformational changes at the nucleotide binding pocket during GTP hydrolysis. 
However, we could not identify many loops around this region, probably due to 
conformational differences between the model and the actual structure. The low 
resolution data have further complicated the matter. If the resolution can be improved 
significantly, either by performing experiments at a more intense beamline or by 
improving the crystal quality, we may be able to rebuild this region and understand any 
conformational variations between different nucleotide liganded states.  
           In Chapter IV, we proposed a model regarding the disassembly of FtsZ filaments 
based on our observation of the GDP bound helical filament. Our key argument is that 
the T7 loop is excluded from the nucleotide binding pocket upon the GTP hydrolysis and 
the γ-phosphate group release. In order to verify this model, it will be critical to seek 
biochemical evidence on whether the GTPase is active during the GDP bound state. 
Obviously, this study is difficult to perform directly. However, we may be able to 
monitor the interaction between the T7 loop with the nucleotide binding pocket of the 
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neighboring monomer during GTP hydrolysis. Fluorescence might be a useful tool for 
this investigation. To achieve this, we should first introduce a fluorophore (e.g. a 
tryptophan residue) into the T7 loop. We could expect to see an increase in both the 
anisotropy and quenching effect during the time course, as T7 loop is gradually 
“pushed” out of the nucleotide binding pocket and fully exposed to the solvent. 
           FtsZ filaments make lateral interactions. Recent studies suggest that the Z-ring is 
likely to be constructed by alignment of many short FtsZ filaments (142, 143). Therefore, 
investigations into the mechanism of lateral interactions are instrumental for 
understanding the architecture of the Z-ring. Though potential lateral interface has been 
proposed based on EM studies (125, 147), little supporting evidence is available. EM 
and mutagenesis may be applied to probe the role of the C-terminal domain and to map 
the interface between protofilaments. Spin label EPR and fluorescence resonance energy 
transfer may also be useful to provide distance information between residues on 
neighboring filaments.  
           Accessory proteins that bind to FtsZ are important for cytokinesis. Many such 
proteins have been studied, mostly from E. coli. Interestingly, in M. tuberculosis, only 
FtsW is found to be FtsZ associated. Future research can be focused on identifying, 
characterizing and crystallizing new FtsZ binding proteins from M. tuberculosis. This 
will not only advance our knowledge of the cell division machinery in mycobacterium, 
but also provide potential drug targets for the treatment of tuberculosis.  
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